



Clinical trial results:

A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults.

Summary

| | |
|--------------------------|-------------------------|
| EudraCT number | 2019-001666-15 |
| Trial protocol | FI CZ EE Outside EU/EEA |
| Global end of trial date | 13 September 2022 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v3 |
| This version publication date | 06 January 2024 |
| First version publication date | 27 March 2023 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 205416 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | Rue de l'Institut, 89, Rixensart, Belgium, 1330 |
| Public contact | GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 24 October 2022 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 13 September 2022 |
| Global end of trial reached? | Yes |
| Global end of trial date | 13 September 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

•Effectiveness of rMenB+OMV NZ and MenABCWY vaccines -against a panel of N.meningitidis serogroup B strains at 1 month(M) after the 3 and 2-dose rMenB+OMV NZ series and last MenABCWY dose when compared to 1 M after MenACWY dose -As the percentages of subjects whose sera kill $\geq 70\%$ of strains tested using enc-hSBA at 1 M after the 3 and 2-dose rMenB+OMV NZ series and 1 M after last MenABCWY dose •Lot-lot consistency of immune responses of 3 lots of MenACWY component of MenABCWY vaccine,as measured by hSBA GMTs at 1 M after last dose •Immunological non-inferiority: MenABCWY versus MenACWY as measured by percentages of subjects achieving a 4-fold rise in hSBA titers at 1 M after last MenABCWY dose and 1 M after MenACWY dose •Effectiveness non-inferiority: MenABCWY versus rMenB+OMV NZ in terms of percentage of samples with bactericidal serum activity at 1 M after last ABCWY dose and 1 M after 3 or 2 dose rMenB+OMV series •Safety and reactogenicity of MenB,MenABCWY and MenACWY vaccines

Protection of trial subjects:

Vaccine administration is to be preceded by a review of the participants medical history (including previous vaccination and possible occurrence of undesirable events) and a general physical examination at the first visit and symptom-directed physical examination before subsequent vaccinations. Protocol procedures including blood sampling were to be done by a qualified healthcare professional. Vaccines/products will be administered only to eligible participants who had no contraindications to any components of the vaccines/products. Participants will be followed-up for 6 months after third vaccination/product administration. The participants will be observed closely for at least 30 minutes following the administration of the vaccine(s)/product(s), with appropriate medical treatment readily available in case of anaphylaxis and/or syncope.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 14 August 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Australia: 295 |
| Country: Number of subjects enrolled | Canada: 229 |
| Country: Number of subjects enrolled | Czechia: 750 |
| Country: Number of subjects enrolled | Estonia: 127 |
| Country: Number of subjects enrolled | Finland: 819 |
| Country: Number of subjects enrolled | Türkiye: 333 |
| Country: Number of subjects enrolled | United States: 1085 |
| Worldwide total number of subjects | 3638 |
| EEA total number of subjects | 1696 |

Notes:

| Subjects enrolled per age group | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 702 |
| Adolescents (12-17 years) | 1459 |
| Adults (18-64 years) | 1477 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

As pre-specified in protocol: -Participant flow, Baseline characteristics, AEs, Effectiveness, and immunogenicity data are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. - Lot-to-lot consistency analysis data are presented for individual ABCWY lot groups (ABCWY-1, ABCWY-2 and ABCWY-3).

Pre-assignment

Screening details:

Out of 3657 participants enrolled, 19 participants did not receive vaccination as they did not meet the eligibility criteria, therefore only 3638 participants were included in the Exposed Set and started the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind ^[1] |
| Roles blinded | Monitor, Data analyst |

Blinding implementation details:

Observer-blinded study. Recipients & study evaluators will be unaware of vaccine administered.

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | MenB_0_2_6 Group |

Arm description:

Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) |
| Investigational medicinal product code | |
| Other name | Menveo |
| Pharmaceutical forms | Powder and solution for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 dose of MenACWY vaccine at Day 211

| | |
|--|--|
| Investigational medicinal product name | Meningococcal Group B Vaccine (rMenB+OMV NZ) |
| Investigational medicinal product code | |
| Other name | Bexsero |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

3 doses of rMenB+OMV NZ vaccine at Day 1, Day 61 and Day 181

| | |
|------------------|----------------|
| Arm title | MenB_0_6 Group |
|------------------|----------------|

Arm description:

Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|---|
| Investigational medicinal product name | Meningococcal Group B Vaccine (rMenB+OMV NZ) |
| Investigational medicinal product code | |
| Other name | Bexsero |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| 2 doses of rMenB+OMV NZ vaccine at Day 1 and Day 181 | |
| Investigational medicinal product name | Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) |
| Investigational medicinal product code | |
| Other name | Menveo |
| Pharmaceutical forms | Powder and solution for solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| 1 dose of MenACWY vaccine at Day 61 | |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| 1 dose of Placebo at Day 211 | |
| Arm title | ABCWY_Pooled |
| Arm description: | |
| Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. | |
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| 2 dose of Placebo at Day 61 and Day 211 | |
| Investigational medicinal product name | Combined Meningococcal Groups A, B, C, W and Y vaccine (MenABCWY) |
| Investigational medicinal product code | MenABCWY |
| Other name | |
| Pharmaceutical forms | Powder and suspension for suspension for injection |
| Routes of administration | Intramuscular use |
| Dosage and administration details: | |
| 2 doses of MenABCWY vaccine at Day 1 and Day 181 | |
| Arm title | ACWY Group |
| Arm description: | |
| Participants received 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care. | |
| Arm type | Active comparator |

| | |
|--|--|
| Investigational medicinal product name | Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) |
| Investigational medicinal product code | |
| Other name | Menveo |
| Pharmaceutical forms | Powder and solution for solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 dose of MenACWY vaccine at Day 1

| | |
|--|--|
| Investigational medicinal product name | Meningococcal Group B Vaccine (rMenB+OMV NZ) |
| Investigational medicinal product code | |
| Other name | Bexsero |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

2 doses of rMenB+OMV NZ vaccine at Day 181 and Day 211

| | |
|--|------------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 dose of Placebo at Day 61

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: This is an Observer-blinded study. Recipients & study evaluators were unaware of the vaccine administered.

| Number of subjects in period 1 | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|--------------------------------------|------------------|----------------|--------------|
| Started | 897 | 906 | 1657 |
| Completed | 797 | 811 | 1497 |
| Not completed | 100 | 95 | 160 |
| Consent withdrawn by subject | 46 | 38 | 54 |
| Adverse event, non-fatal | 7 | 6 | 11 |
| Not specified | 1 | - | 1 |
| MIGRATED / MOVED FROM THE STUDY AREA | 6 | 7 | 9 |
| Lost to follow-up | 32 | 36 | 69 |
| Protocol deviation | 8 | 8 | 16 |

| Number of subjects in period 1 | ACWY Group |
|--------------------------------------|------------|
| Started | 178 |
| Completed | 163 |
| Not completed | 15 |
| Consent withdrawn by subject | 7 |
| Adverse event, non-fatal | 1 |
| Not specified | 1 |
| MIGRATED / MOVED FROM THE STUDY AREA | 1 |
| Lost to follow-up | 4 |

| | |
|--------------------|---|
| Protocol deviation | 1 |
|--------------------|---|

Baseline characteristics

Reporting groups

| | |
|--|------------------|
| Reporting group title | MenB_0_2_6 Group |
| Reporting group description: | |
| Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care. | |
| Reporting group title | MenB_0_6 Group |
| Reporting group description: | |
| Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding. | |
| Reporting group title | ABCWY_Pooled |
| Reporting group description: | |
| Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. | |
| Reporting group title | ACWY Group |
| Reporting group description: | |
| Participants received 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care. | |

| Reporting group values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|--|------------------|----------------|--------------|
| Number of subjects | 897 | 906 | 1657 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 183 | 172 | 320 |
| Adolescents (12-17 years) | 349 | 368 | 666 |
| Adults (18-64 years) | 365 | 366 | 671 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 16.5 | 16.5 | 16.5 |
| standard deviation | ± 4.7 | ± 4.7 | ± 4.7 |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 464 | 446 | 933 |
| Male | 433 | 460 | 724 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 5 | 5 | 3 |
| Asian | 43 | 60 | 71 |
| Black or African American | 33 | 29 | 59 |

| | | | |
|---|-----|-----|------|
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 3 |
| Other, Unspecified | 17 | 20 | 29 |
| White | 796 | 791 | 1492 |

| Reporting group values | ACWY Group | Total | |
|--|------------|-------|--|
| Number of subjects | 178 | 3638 | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 27 | 702 | |
| Adolescents (12-17 years) | 76 | 1459 | |
| Adults (18-64 years) | 75 | 1477 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous Units: years | | | |
| arithmetic mean | 16.9 | | |
| standard deviation | ± 4.6 | - | |
| Sex: Female, Male Units: Participants | | | |
| Female | 100 | 1943 | |
| Male | 78 | 1695 | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 13 | |
| Asian | 9 | 183 | |
| Black or African American | 6 | 127 | |
| Native Hawaiian or Other Pacific Islander | 0 | 7 | |
| Other, Unspecified | 1 | 67 | |
| White | 162 | 3241 | |

End points

End points reporting groups

| | |
|--|------------------|
| Reporting group title | MenB_0_2_6 Group |
| Reporting group description: Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care. | |
| Reporting group title | MenB_0_6 Group |
| Reporting group description: Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding. | |
| Reporting group title | ABCWY_Pooled |
| Reporting group description: Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. | |
| Reporting group title | ACWY Group |
| Reporting group description: Participants received 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care. | |
| Subject analysis set title | ABCWY-1 Group |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211. | |
| Subject analysis set title | ABCWY-2 Group |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211. | |
| Subject analysis set title | ABCWY-3 Group |
| Subject analysis set type | Per protocol |
| Subject analysis set description: Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211. | |

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 3-dose (0,2,6-M), 2-dose(0,6-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY

| | |
|-----------------|--|
| End point title | Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 3-dose (0,2,6-M), 2-dose(0,6-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY ^[1] |
|-----------------|--|

End point description:

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in PPS.

Analysis was performed on blood samples collected from Per Protocol Set (PPS).

| | | | | |
|--|------------------|-----------------|-----------------|--|
| End point type | Primary | | | |
| End point timeframe: | | | | |
| At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group) | | | | |
| Notes: | | | | |
| [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity. | | | | |
| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ACWY Group | |
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 740 | 751 | 147 | |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Number of Blood samples (N=25596,26142,4374) | 13.3 | 14.4 | 79 | |

Statistical analyses

| Statistical analysis title | Statistical analysis 2 |
|---|-----------------------------|
| Statistical analysis description: | |
| To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 2-dose (0,6-M) schedule in MenB_0_6 group when compared to 1 month after the MenACWY dose in the ACWY group. | |
| Comparison groups | MenB_0_6 Group v ACWY Group |
| Number of subjects included in analysis | 898 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[2] |
| Parameter estimate | VE |
| Point estimate | 81.8 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 80.4 |
| upper limit | 83.1 |

Notes:

[2] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for VE against the selected strain panel between the MenB_0_6 and the ACWY groups is above 65%. VE is defined as $1 - RR = (1 - \text{percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group} / \text{percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group}) \times 100$ percentage.

| Statistical analysis title | Statistical analysis 1 |
|--|-------------------------------|
| Statistical analysis description: | |
| To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 3-dose (0,2,6-months) schedule in MenB_0_2_6 group when compared to 1 month after the MenACWY dose in the ACWY group. | |
| Comparison groups | MenB_0_2_6 Group v ACWY Group |

| | |
|---|----------------------------|
| Number of subjects included in analysis | 887 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[3] |
| Parameter estimate | VE (Vaccine Effectiveness) |
| Point estimate | 83.2 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 81.9 |
| upper limit | 84.4 |

Notes:

[3] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for Vaccine Effectiveness (VE) against the selected strain panel between the MenB_0_2_6 and the ACWY groups is above 65%. VE is defined as $1 - \text{Risk Ratio (RR)} = (1 - \text{percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group} / \text{percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group}) \times 100 \text{ percentage}$.

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 2-dose (0,2-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY

| | |
|-----------------|---|
| End point title | Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 2-dose (0,2-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY ^[4] |
|-----------------|---|

End point description:

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in PPS. Analysis was performed on blood samples collected from Per Protocol Set (PPS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity.

| End point values | MenB_0_2_6 Group | ACWY Group | | |
|--|------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 740 | 147 | | |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Number of Blood samples (N=27569,4374) | 16.8 | 79 | | |

Statistical analyses

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: | |
| To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule in MenB_0_2_6 group when compared to 1 month after the MenACWY dose in the ACWY group. | |
| Comparison groups | MenB_0_2_6 Group v ACWY Group |
| Number of subjects included in analysis | 887 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[5] |
| Parameter estimate | VE |
| Point estimate | 78.7 |
| Confidence interval | |
| level | Other: 97.5 % |
| sides | 2-sided |
| lower limit | 77.2 |
| upper limit | 80.1 |

Notes:

[5] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for VE against the selected strain panel between the MenB_0_2_6 and the ACWY groups is above 65%. VE is defined as $1 - \text{RR} = (1 - \text{percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group} / \text{percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group}) \times 100 \text{ percentage}$.

Primary: Geometric mean titers (GMTs) against serogroups A, C, W and Y for each lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 month after the last vaccination of MenABCWY

| | |
|-----------------|---|
| End point title | Geometric mean titers (GMTs) against serogroups A, C, W and Y for each lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 month after the last vaccination of MenABCWY |
|-----------------|---|

End point description:

Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre- specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine. Analysis was performed on PPS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the last vaccination of MenABCWY (Day 211)

| End point values | ABCWY-1 Group | ABCWY-2 Group | ABCWY-3 Group | |
|--|--------------------------|--------------------------|-------------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 452 | 449 | 458 | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Men A (N=448,443,454) | 336.4 (299.3 to 378.0) | 349.9 (311.5 to 393.0) | 390.4 (347.4 to 438.8) | |
| Men C (N= 448,449,456) | 1036.7 (877.6 to 1224.5) | 1130.2 (958.1 to 1333.4) | 888.4 (752.1 to 1049.2) | |
| Men W (N= 452,449,458) | 564.5 (497.9 to 639.9) | 635.5 (561.0 to 719.9) | 640.1 (564.6 to 725.6) | |
| Men Y (N=451,449,457) | 536.7 (464.5 to 620.2) | 623.9 (540.4 to 720.2) | 644.3 (557.6 to 744.6) | |

Statistical analyses

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 1 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-1 Group v ABCWY-2 Group |
| Number of subjects included in analysis | 901 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[6] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.96 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.84 |
| upper limit | 1.1 |

Notes:

[6] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 2 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-1 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 910 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[7] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.86 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.75 |
| upper limit | 0.98 |

Notes:

[7] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|------------------------|
| Statistical analysis title | Statistical analysis 5 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211). | |

| | |
|---|-------------------------------|
| Comparison groups | ABCWY-1 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 910 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[8] |
| Parameter estimate | GMT ratio |
| Point estimate | 1.17 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.97 |
| upper limit | 1.41 |

Notes:

[8] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical analysis 12 |
|-----------------------------------|-------------------------|

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211).

| | |
|---|-------------------------------|
| Comparison groups | ABCWY-2 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 907 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[9] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.97 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.82 |
| upper limit | 1.14 |

Notes:

[9] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 7 |
|-----------------------------------|------------------------|

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211).

| | |
|---|-------------------------------|
| Comparison groups | ABCWY-1 Group v ABCWY-2 Group |
| Number of subjects included in analysis | 901 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[10] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.89 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.77 |
| upper limit | 1.02 |

Notes:

[10] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 8 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-1 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 910 |
| Analysis specification | Pre-specified |
| Analysis type | |
| Parameter estimate | GMT ratio |
| Point estimate | 0.88 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.77 |
| upper limit | 1.02 |

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 9 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-2 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 907 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[11] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.86 |
| upper limit | 1.14 |

Notes:

[11] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 10 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-1 Group v ABCWY-2 Group |

| | |
|---|-----------------------------|
| Number of subjects included in analysis | 901 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[12] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.86 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.73 |
| upper limit | 1.01 |

Notes:

[12] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Statistical analysis 11 |
|-----------------------------------|-------------------------|

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211).

| | |
|---|-------------------------------|
| Comparison groups | ABCWY-1 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 910 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[13] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.83 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.71 |
| upper limit | 0.98 |

Notes:

[13] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 4 |
|-----------------------------------|------------------------|

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211).

| | |
|---|-------------------------------|
| Comparison groups | ABCWY-1 Group v ABCWY-2 Group |
| Number of subjects included in analysis | 901 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[14] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.92 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.76 |
| upper limit | 1.11 |

Notes:

[14] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 3 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-2 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 907 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[15] |
| Parameter estimate | GMT ratio |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.78 |
| upper limit | 1.02 |

Notes:

[15] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

| | |
|---|-------------------------------|
| Statistical analysis title | Statistical analysis 6 |
| Statistical analysis description: To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211). | |
| Comparison groups | ABCWY-2 Group v ABCWY-3 Group |
| Number of subjects included in analysis | 907 |
| Analysis specification | Pre-specified |
| Analysis type | equivalence ^[16] |
| Parameter estimate | GMT ratio |
| Point estimate | 1.27 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.05 |
| upper limit | 1.54 |

Notes:

[16] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Primary: Percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule of rMenB+OMV

| | |
|-----------------|---|
| End point title | Percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule of rMenB+OMV ^{[17][18]} |
|-----------------|---|

End point description:

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill $\geq 70\%$ of strains is above 65%. Analysis was

performed on the FAS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine by assessing the percentages of subjects whose sera kill $\geq 70\%$ of strains tested.

| | | | | |
|------------------------------------|---------------------|--|--|--|
| End point values | MenB_0_2_6 Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 831 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 97.5%) | 84.8 (81.8 to 87.5) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants whose sera kill Greater Than or Equal to (\geq) 70% of the strains tested using enc-hSBA at 1 month after the 3-dose (0,2,6-M) schedule of rMenB+OMV and 2-dose(0,6-M) schedule of rMenB+OMV

| | |
|-----------------|---|
| End point title | Percentage of participants whose sera kill Greater Than or Equal to (\geq) 70% of the strains tested using enc-hSBA at 1 month after the 3-dose (0,2,6-M) schedule of rMenB+OMV and 2-dose(0,6-M) schedule of rMenB+OMV ^{[19][20]} |
|-----------------|---|

End point description:

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill $\geq 70\%$ of strains is above 65%. Analysis was performed on the Full Analysis Set (FAS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine by assessing the percentages of subjects whose sera kill $\geq 70\%$ of strains tested.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | | |
|------------------------------------|---------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 790 | 813 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 97.5%) | 93.4 (91.2 to 95.2) | 89.8 (87.2 to 92) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants with 4-fold rise in hSBA titers against N. meningitidis serogroups A, C, W and Y at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group), relative to baseline

| | |
|-----------------|---|
| End point title | Percentage of participants with 4-fold rise in hSBA titers against N. meningitidis serogroups A, C, W and Y at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group), relative to baseline ^[21] |
|-----------------|---|

End point description:

Four-fold rise is defined as: If the pre-vaccination hSBA titer is < 4, then post-vaccination hSBA titer should be ≥ 16 . If the pre-vaccination hSBA titer is \geq limit of detection (LOD) but < LL of quantification (LLOQ), then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. If the pre-vaccination hSBA titer is \geq LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on PPS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

| End point values | ABCWY_Pooled | ACWY Group | | |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1196 | 119 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Men A (N=1170,112) | 97.0 (95.9 to 97.9) | 85.7 (77.8 to 91.6) | | |
| Men C (N=1189,114) | 97.2 (96.1 to 98.1) | 50.0 (40.5 to 59.5) | | |
| Men W (N=1185,115) | 97.0 (95.9 to 97.9) | 61.7 (52.2 to 70.6) | | |
| Men Y (N=1196,119) | 96.7 (95.6 to 97.7) | 69.7 (60.7 to 77.8) | | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|---|--|
| Statistical analysis description: | |
| To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup A at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination. | |
| Comparison groups | ABCWY_Pooled v ACWY Group |
| Number of subjects included in analysis | 1315 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[22] |
| Parameter estimate | Difference in percentage of participants |
| Point estimate | 11.29 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 5.88 |
| upper limit | 19.01 |

Notes:

[22] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

| Statistical analysis title | Statistical Analysis 3 |
|---|--|
| Statistical analysis description: | |
| To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup W at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination. | |
| Comparison groups | ABCWY_Pooled v ACWY Group |
| Number of subjects included in analysis | 1315 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[23] |
| Parameter estimate | Difference in percentage of participants |
| Point estimate | 35.31 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 26.88 |
| upper limit | 44.49 |

Notes:

[23] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

| Statistical analysis title | Statistical Analysis 4 |
|---|---------------------------|
| Statistical analysis description: | |
| To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup Y at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination. | |
| Comparison groups | ABCWY_Pooled v ACWY Group |

| | |
|---|--|
| Number of subjects included in analysis | 1315 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[24] |
| Parameter estimate | Difference in percentage of participants |
| Point estimate | 26.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 19.38 |
| upper limit | 35.81 |

Notes:

[24] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup C at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination.

| | |
|---|--|
| Comparison groups | ABCWY_Pooled v ACWY Group |
| Number of subjects included in analysis | 1315 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[25] |
| Parameter estimate | Difference in percentage of participants |
| Point estimate | 47.22 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 38.14 |
| upper limit | 56.3 |

Notes:

[25] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group)

| | |
|-----------------|---|
| End point title | Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group) ^[26] |
|-----------------|---|

End point description:

The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY- 3 groups were pooled into a single group. Analysis was performed on blood samples collected from PPS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

| End point values | ABCWY_Pooled | ACWY Group | | |
|---|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1356 | 147 | | |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Number of Blood samples analyzed (N=25715,4374) | 17.4 | 79 | | |

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|
|----------------------------|------------------------|

Statistical analysis description:

To demonstrate the effectiveness of the MenABCWY vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by enc-hSBA at 1 month after the last MenABCWY vaccination (Day 211) when compared to 1 month after the MenACWY vaccination.

| | |
|---|---------------------------|
| Comparison groups | ABCWY_Pooled v ACWY Group |
| Number of subjects included in analysis | 1503 |
| Analysis specification | Pre-specified |
| Analysis type | other ^[27] |
| Parameter estimate | VE |
| Point estimate | 77.9 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 76.6 |
| upper limit | 79.2 |

Notes:

[27] - Effectiveness of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for VE against the selected strain panel between the ABCWY and the ACWY groups is above 65%. VE is defined as $1 - \text{RR} = (1 - \text{percentage of samples without bactericidal serum activity at 1:4 dilution in ABCWY_Pooled group} / \text{percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group}) \times 100 \text{ percentage}$.

Primary: Percentage of blood samples with bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose (pooled lots) and 2-dose(0,2-M) schedule of rMenB+OMV

| | |
|-----------------|--|
| End point title | Percentage of blood samples with bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose (pooled lots) and 2-dose(0,2-M) schedule of rMenB+OMV ^[28] |
|-----------------|--|

End point description:

The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on blood samples collected from PPS, which included participants who

received at least 1 dose of the study treatment to which they were randomized and have post-vaccination data for the specified analysis at specified timepoints and did not have any protocol deviations that lead to exclusion from the PPS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity.

| End point values | MenB_0_2_6 Group | ABCWY_Pooled | | |
|---|------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 740 | 1356 | | |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Number of Blood samples Analyzed (27569, 25715) | 83.1 | 82.5 | | |

Statistical analyses

| | |
|----------------------------|------------------------|
| Statistical analysis title | Statistical analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

To demonstrate the non-inferiority of the effectiveness of the MenABCWY vaccine (0,6-months schedule) compared to the rMenB+OMV NZ vaccine (0,2-months) in terms of percentage of samples with bactericidal serum activity using enc-hSBA against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains.

| | |
|---|--|
| Comparison groups | MenB_0_2_6 Group v ABCWY_Pooled |
| Number of subjects included in analysis | 2096 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[29] |
| Parameter estimate | Difference in percentage of participants |
| Point estimate | -0.61 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.25 |
| upper limit | 0.03 |

Notes:

[29] - Non-inferiority of MenABCWY to rMenB+OMV NZ is demonstrated if LL of the 2-sided 95% CI for the difference in percentages of samples with bactericidal serum activity at 1:4 dilution is above -5%.

Primary: Percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA at 1 month after the last vaccination in the ABCWY Group (pooled lots)

| | |
|-----------------|--|
| End point title | Percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA at 1 month after the last vaccination in the ABCWY Group (pooled lots) ^{[30][31]} |
|-----------------|--|

End point description:

The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill $\geq 70\%$ of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill $\geq 70\%$ of strains tested for MenABCWY is above 65%. Analysis was performed on the FAS.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the last vaccination of MenABCWY (Day 211)

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine.

| End point values | ABCWY_Pooled | | | |
|-----------------------------------|---------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 817 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 84.1 (81.4 to 86.5) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after the first study intervention administration

| | |
|-----------------|--|
| End point title | Number of participants with any solicited local adverse events (AEs) after the first study intervention administration ^[32] |
|-----------------|--|

End point description:

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the first study intervention administration occurring at Day 1

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 885 | 894 | 1638 | 178 |
| Units: participants | | | | |
| Pain | 807 | 819 | 1503 | 67 |
| Erythema | 90 | 86 | 216 | 11 |
| Swelling | 87 | 89 | 217 | 11 |
| Induration | 60 | 64 | 150 | 7 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after the second study intervention administration

| | |
|-----------------|---|
| End point title | Number of participants with any solicited local adverse events (AEs) after the second study intervention administration ^[33] |
|-----------------|---|

End point description:

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the second study intervention administration occurring at Day 61

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 823 | 813 | 1511 | 161 |
| Units: participants | | | | |
| Pain | 714 | 224 | 205 | 30 |
| Erythema | 89 | 26 | 5 | 1 |
| Swelling | 99 | 22 | 5 | 1 |
| Induration | 67 | 19 | 6 | 0 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after

the third study intervention administration

| | |
|-----------------|--|
| End point title | Number of participants with any solicited local adverse events (AEs) after the third study intervention administration ^[34] |
|-----------------|--|

End point description:

Assessed solicited local adverse events were injection site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the third study intervention administration occurring at Day 181

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 765 | 759 | 1428 | 148 |
| Units: participants | | | | |
| Pain | 677 | 676 | 1258 | 126 |
| Erythema | 118 | 87 | 168 | 11 |
| Swelling | 107 | 85 | 176 | 13 |
| Induration | 52 | 57 | 114 | 12 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited systemic AEs after the first study intervention administration

| | |
|-----------------|--|
| End point title | Number of participants with any solicited systemic AEs after the first study intervention administration ^[35] |
|-----------------|--|

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature $\geq 38.0^{\circ}\text{C}$]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the first study intervention administration occurring at Day 1

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 885 | 894 | 1638 | 178 |
| Units: participants | | | | |
| Fatigue | 423 | 414 | 828 | 78 |
| Nausea | 112 | 111 | 242 | 27 |
| Myalgia | 92 | 106 | 242 | 13 |
| Arthralgia | 56 | 70 | 133 | 17 |
| Headache | 358 | 330 | 681 | 69 |
| Fever (C) | 19 | 17 | 55 | 3 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited systemic AEs after the second study intervention administration

| | |
|-----------------|---|
| End point title | Number of participants with any solicited systemic AEs after the second study intervention administration ^[36] |
|-----------------|---|

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature $\geq 38.0^{\circ}\text{C}$]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the second study intervention administration occurring at Day 61

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 823 | 813 | 1511 | 161 |
| Units: participants | | | | |
| Fatigue | 372 | 228 | 345 | 36 |
| Nausea | 104 | 56 | 85 | 18 |
| Myalgia | 110 | 46 | 55 | 3 |
| Arthralgia | 72 | 332 | 35 | 6 |
| Headache | 301 | 223 | 332 | 31 |
| Fever (C) | 22 | 12 | 18 | 1 |

Statistical analyses

Primary: Number of participants with any solicited systemic AEs after the third study intervention administration

| | |
|-----------------|--|
| End point title | Number of participants with any solicited systemic AEs after the third study intervention administration ^[37] |
|-----------------|--|

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature $\geq 38.0^{\circ}\text{C}$]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During 7 days after the third study intervention administration occurring at Day 181

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 765 | 759 | 1428 | 148 |
| Units: participants | | | | |
| Fatigue | 374 | 341 | 602 | 56 |
| Nausea | 94 | 84 | 147 | 14 |
| Myalgia | 106 | 109 | 168 | 17 |
| Arthralgia | 71 | 53 | 104 | 7 |
| Headache | 302 | 284 | 509 | 39 |
| Fever (C) | 21 | 23 | 27 | 2 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the first study intervention administration

| | |
|-----------------|---|
| End point title | Number of participants with any unsolicited AEs after the first study intervention administration ^[38] |
|-----------------|---|

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 30 days after the first study intervention administration occurring at Day 1

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 893 | 900 | 1648 | 178 |
| Units: participants | 90 | 124 | 217 | 29 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the second study intervention administration

| | |
|-----------------|--|
| End point title | Number of participants with any unsolicited AEs after the second study intervention administration ^[39] |
|-----------------|--|

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 30 days after the second study intervention administration occurring at Day 61

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 851 | 855 | 1579 | 170 |
| Units: participants | 106 | 88 | 160 | 15 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the third study intervention administration

| | |
|-----------------|---|
| End point title | Number of participants with any unsolicited AEs after the third study intervention administration ^[40] |
|-----------------|---|

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

During the 30 days after the third study intervention administration occurring at Day 181

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 815 | 823 | 1521 | 166 |
| Units: participants | 96 | 94 | 183 | 19 |

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs

| | |
|-----------------|---|
| End point title | Number of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs ^[41] |
|-----------------|---|

End point description:

A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Throughout the study period (Day 1 to Day 361)

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|-----------------------------|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 893 | 900 | 1648 | 178 |
| Units: participants | | | | |
| SAEs | 20 | 22 | 25 | 5 |
| AEs leading to withdrawal | 6 | 4 | 4 | 1 |
| AESIs | 1 | 1 | 6 | 0 |
| medically attended AEs | 238 | 288 | 479 | 44 |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose and 3-dose (0,2,6-M), 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY

| | |
|-----------------|---|
| End point title | Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose and 3-dose (0,2,6-M), 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY |
|-----------------|---|

End point description:

The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in FAS. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group, ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the MenB_0_2_6 group [3 dose schedule], MenB_0_6 group, ABCWY_Pooled group and Day 31 for the MenACWY group)

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|--|------------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 790 | 813 | 817 | 136 |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Meningitis B M10713 Ab (N= 252,247,251,45) | 0.4 | 0.4 | 1.2 | 15.6 |
| Meningitis B M08641 Ab (N= 229,259,237,29) | 6.6 | 6.2 | 8 | 96.6 |
| Meningitis B M12898 Ab (N= 242,265,249,41) | 8.4 | 11.4 | 12.1 | 68.1 |
| Meningitis B M09150 Ab (N= 249,222,273,36) | 5.2 | 8.5 | 12.6 | 73 |

| | | | | |
|--|------|------|------|------|
| Meningitis B M09401 Ab (N= 243,275,288,49) | 50.2 | 46.5 | 57 | 98 |
| Meningitis B M07463 Ab (N= 259,274,256,49) | 1.5 | 1.8 | 3.5 | 49 |
| Meningitis B M10496 Ab (N= 263,261,257,47) | 54.4 | 47.9 | 68.9 | 100 |
| Meningitis B M14530 Ab (N= 241,257,284,37) | 2.1 | 1.6 | 3.2 | 100 |
| Meningitis B M15668 Ab (N= 237,270,262,49) | 0.8 | 2.2 | 0.8 | 87.8 |
| Meningitis B M14028 Ab (N= 246,282,283,37) | 2.8 | 5.7 | 4.9 | 100 |
| Meningitis B M09909 Ab (N= 244,265,261,42) | 79.1 | 83.4 | 86.2 | 100 |
| Meningitis B M14385 Ab (N= 235,237,259,43) | 0.9 | 0.8 | 0 | 16.3 |
| Meningitis B M07992 Ab (N= 237,252,274,36) | 0.4 | 0 | 0.4 | 0 |
| Meningitis B M09155 Ab (N= 234,255,230,45) | 1.7 | 2 | 1.3 | 97.8 |
| Meningitis B M13085 Ab (N= 256,253,255,44) | 13.5 | 27.5 | 26.6 | 69.3 |
| Meningitis B M18303 Ab (N= 241,252,264,40) | 2.9 | 4 | 9.5 | 100 |
| Meningitis B M18711 Ab (N= 252,237,262,33) | 5.2 | 4.2 | 9.5 | 75.8 |
| Meningitis B M15009 Ab (N= 262,254,242,37) | 11.8 | 20.5 | 31.8 | 86.5 |
| Meningitis B M07773 Ab (N= 269,262,251,35) | 0.7 | 0.4 | 0.4 | 74.3 |
| Meningitis B M09662 Ab (N= 267,266,255,48) | 61.4 | 50.8 | 66.3 | 95.8 |
| Meningitis B M18483 Ab (N= 228,233,222,37) | 3 | 5.1 | 3.7 | 72.2 |
| Meningitis B M11906 Ab (N= 264,271,260,39) | 23.7 | 30.3 | 39.9 | 84.7 |
| Meningitis B M14987 Ab (N= 250,274,270,35) | 1.2 | 8.8 | 12.7 | 68.6 |
| Meningitis B M12014 Ab (N= 249,270,254,46) | 0.4 | 0.7 | 1.2 | 67.4 |
| Meningitis B M18200 Ab (N= 228,247,242,47) | 6.3 | 14.8 | 14.9 | 33.7 |
| Meningitis B M08912 Ab (N= 225,247,237,40) | 0.4 | 0 | 0 | 0 |
| Meningitis B M16748 Ab (N= 262,252,260,45) | 0.8 | 0 | 0 | 0 |
| Meningitis B M08152 Ab (N= 208,215,223,35) | 22.4 | 25.3 | 32.8 | 66.8 |
| Meningitis B M09973 Ab (N= 252,270,247,48) | 0.8 | 1.1 | 3 | 83.3 |
| Meningitis B M15352 Ab (N= 237,249,245,33) | 8.9 | 8.4 | 17.8 | 97 |
| Meningitis B M15165 Ab (N= 249,250,240,42) | 0 | 1.2 | 2.1 | 92.9 |
| Meningitis B M08127 Ab (N= 269,250,287,51) | 0.7 | 0.4 | 0.7 | 84.3 |
| Meningitis B M18347 Ab (N= 234,262,239,44) | 45.4 | 50.9 | 51.8 | 82.1 |
| Meningitis B M12500 Ab (N= 223,253,241,43) | 0.9 | 2.4 | 2.5 | 95.3 |
| Meningitis B M07499 Ab (N= 242,251,256,51) | 70.7 | 75.7 | 80.1 | 100 |

| | | | | |
|---|------|------|------|------|
| Meningitis B M09960 Ab (N=243,247,251,33) | 1.2 | 0 | 0 | 3 |
| Meningitis B M18045 Ab (N=236,251,272,41) | 0 | 0.4 | 0 | 92.7 |
| Meningitis B M10548 Ab (N=234,243,261,58) | 8.1 | 11.9 | 12.5 | 74.1 |
| Meningitis B M09354 Ab (N=246,240,241,40) | 1.2 | 1.3 | 0 | 80 |
| Meningitis B M11051 Ab (N=246,282,247,46) | 61 | 64.2 | 66.7 | 97.8 |
| Meningitis B M10104 Ab (N=247,241,239,41) | 58.7 | 52.3 | 63.5 | 97.6 |
| Meningitis B M13361 Ab (N=258,268,250,34) | 0.8 | 0.4 | 0.4 | 85.3 |
| Meningitis B M11042 Ab (N=217,249,254,43) | 19.8 | 25.5 | 33.5 | 85.7 |
| Meningitis B M18467 Ab (N=255,223,250,47) | 1.2 | 0.4 | 0.8 | 78.7 |
| Meningitis B M11113 Ab (N=255,253,269,51) | 30.1 | 39.5 | 49.5 | 75.2 |
| Meningitis B M07253 Ab (N=260,245,255,40) | 34.7 | 33.8 | 50.2 | 86.4 |
| Meningitis B M07356 Ab (N=235,235,266,29) | 0.4 | 0 | 1.1 | 41.4 |
| Meningitis B M10710 Ab (N=254,253,270,40) | 1.6 | 2 | 1.4 | 92.5 |
| Meningitis B M17147 Ab (N=261,279,214,41) | 2.3 | 5.4 | 2.3 | 100 |
| Meningitis B M14401 Ab (N=241,266,253,43) | 1.7 | 0.4 | 1.2 | 83.7 |
| Meningitis B M14293 Ab (N=251,247,224,47) | 45.8 | 25.1 | 45.2 | 95.7 |
| Meningitis B M08540 Ab (N=258,261,222,34) | 1.6 | 0.8 | 0 | 38.2 |
| Meningitis B M07960 Ab (N=277,241,241,39) | 3.6 | 4.1 | 1.8 | 94.9 |
| Meningitis B M16135 Ab (N=254,230,257,41) | 0 | 1.7 | 0.8 | 95.1 |
| Meningitis B M14548 Ab (N=267,266,274,38) | 2.6 | 3.4 | 3.2 | 94.7 |
| Meningitis B M09181 Ab (N=228,276,240,43) | 0 | 0.4 | 0.4 | 72.1 |
| Meningitis B M14224 Ab (N=248,279,277,40) | 0.4 | 0.4 | 0 | 82.5 |
| Meningitis B M07452 Ab (N=260,260,245,47) | 2.7 | 8.1 | 17.1 | 85.1 |
| Meningitis B M13520 Ab (N=217,222,242,30) | 3.2 | 0.9 | 0 | 66.7 |
| Meningitis B M09385 Ab (N=228,252,265,32) | 0.4 | 1.6 | 0 | 46.9 |
| Meningitis B M14881 Ab (N=240,278,277,40) | 4.2 | 5.8 | 10 | 95 |
| Meningitis B M13252 Ab (N=279,241,262,50) | 0.7 | 1.2 | 0.4 | 98 |
| Meningitis B M07818 Ab (N=232,244,228,43) | 0.4 | 0.8 | 1.3 | 90.7 |
| Meningitis B M09914 Ab (N=281,257,258,49) | 85.4 | 86.8 | 88.3 | 98 |
| Meningitis B M15083 Ab (N=231,262,241,40) | 51.4 | 56.7 | 61 | 84.5 |
| Meningitis B M11290 Ab (N=264,266,221,34) | 61.4 | 61.7 | 67.4 | 100 |

| | | | | |
|---|------|------|------|------|
| Meningitis B M14988 Ab (N=241,269,246,40) | 0.4 | 0 | 1.2 | 60 |
| Meningitis B M10536 Ab (N=228,223,260,36) | 19.7 | 14.3 | 14.3 | 91.7 |
| Meningitis B M08959 Ab (N=252,241,258,47) | 0.8 | 0.4 | 1.9 | 85.1 |
| Meningitis B M08785 Ab (N=251,249,260,39) | 0.8 | 0.4 | 0.4 | 53.8 |
| Meningitis B M07245 Ab (N=238,248,230,43) | 0 | 0 | 0.9 | 23.3 |
| Meningitis B M19315 Ab (N=262,254,255,34) | 3.8 | 3.1 | 9.5 | 79.4 |
| Meningitis B M14376 Ab (N=234,220,222,41) | 0 | 1.4 | 0 | 92.7 |
| Meningitis B M08994 Ab (N=226,253,233,31) | 2.5 | 7.6 | 6.9 | 62.7 |
| Meningitis B M11646 Ab (N=241,224,250,36) | 0 | 1.3 | 2 | 83.3 |
| Meningitis B M13362 Ab (N=259,228,231,49) | 0 | 0.4 | 0.4 | 81.6 |
| Meningitis B M08080 Ab (N=236,247,242,45) | 27.4 | 41 | 51.6 | 85.7 |
| Meningitis B M08370 Ab (N=265,262,251,43) | 2.3 | 1.5 | 3.7 | 97.7 |
| Meningitis B M08129 Ab (N=245,254,257,28) | 4.1 | 4.7 | 7 | 71.4 |
| Meningitis B M07111 Ab (N=231,254,270,33) | 0.4 | 1.2 | 0.7 | 90.9 |
| Meningitis B M07537 Ab (N=241,242,263,47) | 95.9 | 95.9 | 97.7 | 100 |
| Meningitis B M13438 Ab (N=255,262,282,50) | 1.2 | 0.8 | 0 | 16 |
| Meningitis B M10661 Ab (N=246,275,273,33) | 2 | 2.9 | 2.9 | 97 |
| Meningitis B M10920 Ab (N=247,252,275,34) | 29.1 | 27.8 | 37.8 | 91.2 |
| Meningitis B M15564 Ab (N=240,273,263,40) | 0.4 | 0.7 | 0.8 | 77.5 |
| Meningitis B M10934 Ab (N=273,241,256,36) | 0.4 | 0.8 | 0.8 | 100 |
| Meningitis B M09400 Ab (N=254,281,279,39) | 0.8 | 1.8 | 0.4 | 97.4 |
| Meningitis B M08781 Ab (N=221,258,229,28) | 71.9 | 74.4 | 78.2 | 100 |
| Meningitis B M09173 Ab (N=238,249,247,42) | 0.4 | 0.4 | 0.8 | 95.2 |
| Meningitis B M14113 Ab (N=228,255,264,42) | 15.4 | 21.2 | 22 | 100 |
| Meningitis B M08389 Ab (N=254,259,250,45) | 10.7 | 7 | 11.7 | 87.2 |
| Meningitis B M16822 Ab (N=239,233,264,34) | 67.8 | 76.4 | 82.2 | 100 |
| Meningitis B M10995 Ab (N=268,258,239,47) | 5.2 | 17.8 | 30.6 | 85.1 |
| Meningitis B M08780 Ab (N=236,259,260,40) | 1.3 | 0.8 | 1.5 | 92.5 |
| Meningitis B M09910 Ab (N=247,246,257,43) | 1.6 | 1.2 | 1.2 | 93 |
| Meningitis B M08320 Ab (N=262,238,253,45) | 33.6 | 39.7 | 43.3 | 87 |
| Meningitis B M14879 Ab (N=239,242,247,47) | 2.1 | 2.1 | 6.1 | 21.3 |

| | | | | |
|---|------|------|------|------|
| Meningitis B M09345 Ab (N=251,257,282,48) | 19.3 | 20.1 | 33.4 | 81.2 |
| Meningitis B M14594 Ab (N=245,241,238,44) | 20.8 | 27.4 | 41.2 | 97.7 |
| Meningitis B M07621 Ab (N=251,260,263,40) | 1.2 | 1.2 | 1.1 | 77.5 |
| Meningitis B M13568 Ab (N=261,264,253,40) | 5.4 | 3.8 | 3.9 | 95 |
| Meningitis B M18017 Ab (N=246,247,258,31) | 0.4 | 0 | 1.6 | 96.8 |
| Meningitis B M08420 Ab (N=243,255,256,40) | 0.8 | 0.4 | 1.6 | 95 |
| Meningitis B M07959 Ab (N=236,237,254,35) | 1.7 | 2.5 | 1.7 | 97.1 |
| Meningitis B M06970 Ab (N=236,261,253,32) | 19.6 | 17.6 | 30.2 | 85.7 |
| Meningitis B M10491 Ab (N=239,262,227,39) | 5.4 | 8.4 | 17 | 82.1 |
| Meningitis B M13569 Ab (N=221,243,247,31) | 0.9 | 2.9 | 1.2 | 96.8 |
| Meningitis B M10182 Ab (N=229,234,256,44) | 0.4 | 0 | 0 | 0 |
| Meningitis B M13547 Ab (N=251,258,238,44) | 2.4 | 7 | 4.7 | 47.7 |
| Meningitis B M15276 Ab (N=231,231,259,41) | 0.4 | 0 | 1.5 | 87.8 |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers against N.meningitidis group B strains at 1 month after last MenABCWY dose (ABCWY group-pooled lots) and 1 month after 2-dose(0,2-M) schedule of rMenB+OMV NZ relative to baseline

| | |
|-----------------|---|
| End point title | Percentage of participants with 4-fold rise in hSBA titers against N.meningitidis group B strains at 1 month after last MenABCWY dose (ABCWY group-pooled lots) and 1 month after 2-dose(0,2-M) schedule of rMenB+OMV NZ relative to baseline ^[42] |
|-----------------|---|

End point description:

The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥ 16 for participants with a pre-vaccination hSBA titre < 4 ; a post-vaccination hSBA titre ≥ 4 times the LLOQ for participants with a pre-vaccination hSBA titre $\geq \text{LOD}$ and $< \text{LLOQ}$; a post-vaccination hSBA titre ≥ 4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre $\geq \text{LLOQ}$. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. The analysis was performed on the PPS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule]) compared to Day 1 (Baseline)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immunological noninferiority of the MenABCWY vaccine compared to the rMenB+OMV vaccine.

| End point values | MenB_0_2_6 Group | ABCWY_Pooled | | |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 719 | 678 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| fHbp (M14459) Ab (N=719,675) | 74.7 (71.3 to 77.8) | 79.7 (76.5 to 82.7) | | |
| NadA (96217) Ab (N=717,671) | 96.4 (94.7 to 97.6) | 92.7 (90.5 to 94.5) | | |
| NHBA (M13520) Ab (N=718,678) | 58.6 (54.9 to 62.3) | 61.9 (58.2 to 65.6) | | |
| PorA (NZ98/254) Ab (N=704,642) | 53.3 (49.5 to 57.0) | 42.2 (38.4 to 46.1) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of blood samples without bactericidal serum activity using enc-hSBA against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY

| | |
|-----------------|---|
| End point title | Percentage of blood samples without bactericidal serum activity using enc-hSBA against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of |
|-----------------|---|

End point description:

The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.

Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in FAS.

Analysis was performed on blood samples collected from FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2 dose schedule] and Day 31 for the MenACWY group)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

| End point values | MenB_0_2_6 Group | ACWY Group | | |
|------------------------------------|------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 893 | 173 | | |
| Units: Percentage of blood samples | | | | |
| number (not applicable) | | | | |
| Meningitis B M10713 Ab (N=266,45) | 1.9 | 15.6 | | |
| Meningitis B M08641 Ab (N=250,29) | 11.2 | 96.6 | | |
| Meningitis B M12898 Ab (N=260,41) | 12.4 | 69 | | |
| Meningitis B M09150 Ab (N=250,36) | 9.3 | 68.6 | | |
| Meningitis B M09401 Ab (N=253,49) | 47 | 98 | | |
| Meningitis B M07463 Ab (N=265,49) | 2.6 | 49 | | |
| Meningitis B M10496 Ab (N=277,47) | 50.5 | 100 | | |
| Meningitis B M14530 Ab (N=254,37) | 3.9 | 100 | | |
| Meningitis B M15668 Ab (N=252,49) | 0.4 | 87.8 | | |
| Meningitis B M14028 Ab (N=257,37) | 5.4 | 100 | | |
| Meningitis B M09909 Ab (N=266,42) | 82 | 100 | | |
| Meningitis B M14385 Ab (N=227,43) | 0 | 16.3 | | |
| Meningitis B M07992 Ab (N=249,36) | 0 | 0 | | |
| Meningitis B M09155 Ab (N=243,45) | 2.5 | 97.8 | | |
| Meningitis B M13085 Ab (N=271,44) | 21 | 66.4 | | |
| Meningitis B M18303 Ab (N=252,40) | 9.1 | 100 | | |
| Meningitis B M18711 Ab (N=261,33) | 7.7 | 75.8 | | |
| Meningitis B M15009 Ab (N=243,37) | 22.2 | 86.5 | | |
| Meningitis B M07773 Ab (N=281,35) | 1.1 | 74.3 | | |
| Meningitis B M09662 Ab (N=284,48) | 58.1 | 95.8 | | |
| Meningitis B M18483 Ab (N=234,37) | 4.3 | 77.3 | | |
| Meningitis B M11906 Ab (N=277,39) | 38.8 | 85.3 | | |
| Meningitis B M14987 Ab (N=264,35) | 10.7 | 62.3 | | |
| Meningitis B M12014 Ab (N=267,46) | 0.7 | 63.2 | | |
| Meningitis B M18200 Ab (N=241,47) | 12.1 | 34.4 | | |
| Meningitis B M08912 Ab (N=246,40) | 0 | 0 | | |
| Meningitis B M16748 Ab (N=281,45) | 0 | 0 | | |
| Meningitis B M08152 Ab (N=224,35) | 35.6 | 67.2 | | |
| Meningitis B M09973 Ab (N=271,48) | 1.5 | 83.3 | | |
| Meningitis B M15352 Ab (N=219,33) | 11.9 | 97 | | |
| Meningitis B M15165 Ab (N=265,42) | 0.8 | 92.9 | | |
| Meningitis B M08127 Ab (N=285,51) | 0.4 | 84.3 | | |
| Meningitis B M18347 Ab (N=249,44) | 60.5 | 80.4 | | |
| Meningitis B M12500 Ab (N=236,43) | 3.4 | 95.3 | | |
| Meningitis B M07499 Ab (N=259,51) | 81.1 | 100 | | |
| Meningitis B M09960 Ab (N=251,33) | 4.4 | 3 | | |
| Meningitis B M18045 Ab (N=247,41) | 0 | 92.7 | | |
| Meningitis B M10548 Ab (N=244,58) | 11.9 | 74.1 | | |
| Meningitis B M09354 Ab (N=258,40) | 0.4 | 80 | | |
| Meningitis B M11051 Ab (N=270,46) | 68.9 | 97.8 | | |
| Meningitis B M10104 Ab (N=249,41) | 61.8 | 97.6 | | |
| Meningitis B M13361 Ab (N=269,34) | 0.4 | 85.3 | | |
| Meningitis B M11042 Ab (N=210,43) | 30.1 | 84.2 | | |
| Meningitis B M18467 Ab (N=272,47) | 0.4 | 78.7 | | |
| Meningitis B M11113 Ab (N=273,51) | 43.1 | 75.6 | | |
| Meningitis B M07253 Ab (N=274,40) | 43.3 | 85.3 | | |

| | | | | |
|-----------------------------------|------|------|--|--|
| Meningitis B M07356 Ab (N=247,29) | 0 | 41.4 | | |
| Meningitis B M10710 Ab (N=269,40) | 2.2 | 92.5 | | |
| Meningitis B M17147 Ab (N=274,41) | 5.1 | 100 | | |
| Meningitis B M14401 Ab (N=251,43) | 0.8 | 83.7 | | |
| Meningitis B M14293 Ab (N=264,47) | 36.4 | 95.7 | | |
| Meningitis B M08540 Ab (N=271,34) | 0.4 | 38.2 | | |
| Meningitis B M07960 Ab (N=292,39) | 4.1 | 94.9 | | |
| Meningitis B M16135 Ab (N=263,41) | 0.8 | 95.1 | | |
| Meningitis B M14548 Ab (N=286,38) | 2.8 | 94.7 | | |
| Meningitis B M09181 Ab (N=252,43) | 0 | 72.1 | | |
| Meningitis B M14224 Ab (N=268,40) | 0.7 | 82.5 | | |
| Meningitis B M07452 Ab (N=267,47) | 13.5 | 85.1 | | |
| Meningitis B M13520 Ab (N=234,30) | 0.9 | 66.7 | | |
| Meningitis B M09385 Ab (N=230,32) | 2.2 | 46.9 | | |
| Meningitis B M14881 Ab (N=258,40) | 14.7 | 95 | | |
| Meningitis B M13252 Ab (N=286,50) | 3.1 | 98 | | |
| Meningitis B M07818 Ab (N=249,43) | 0.4 | 90.7 | | |
| Meningitis B M09914 Ab (N=293,49) | 87.7 | 98 | | |
| Meningitis B M15083 Ab (N=260,40) | 63.7 | 78 | | |
| Meningitis B M11290 Ab (N=278,34) | 70.5 | 100 | | |
| Meningitis B M14988 Ab (N=251,40) | 0.4 | 60 | | |
| Meningitis B M10536 Ab (N=241,36) | 23.2 | 91.7 | | |
| Meningitis B M08959 Ab (N=267,47) | 0.4 | 85.1 | | |
| Meningitis B M08785 Ab (N=262,39) | 0.4 | 53.8 | | |
| Meningitis B M07245 Ab (N=254,43) | 0 | 23.3 | | |
| Meningitis B M19315 Ab (N=270,34) | 6.3 | 79.4 | | |
| Meningitis B M14376 Ab (N=269,41) | 0 | 92.7 | | |
| Meningitis B M08994 Ab (N=233,31) | 8.9 | 55.7 | | |
| Meningitis B M11646 Ab (N=252,36) | 1.6 | 83.3 | | |
| Meningitis B M13362 Ab (N=272,49) | 1.5 | 81.6 | | |
| Meningitis B M08080 Ab (N=244,45) | 46.8 | 87.1 | | |
| Meningitis B M08370 Ab (N=280,43) | 3.9 | 97.7 | | |
| Meningitis B M08129 Ab (N=242,28) | 7.4 | 71.4 | | |
| Meningitis B M07111 Ab (N=244,33) | 0.4 | 90.9 | | |
| Meningitis B M07537 Ab (N=253,47) | 96.4 | 100 | | |
| Meningitis B M13438 Ab (N=263,50) | 0.4 | 16 | | |
| Meningitis B M10661 Ab (N=259,33) | 2.7 | 97 | | |
| Meningitis B M10920 Ab (N=259,34) | 50.2 | 91.2 | | |
| Meningitis B M15564 Ab (N=258,40) | 0.8 | 77.5 | | |
| Meningitis B M10934 Ab (N=286,36) | 0 | 100 | | |
| Meningitis B M09400 Ab (N=261,39) | 1.1 | 97.4 | | |
| Meningitis B M08781 Ab (N=223,28) | 75.8 | 100 | | |
| Meningitis B M09173 Ab (N=244,42) | 0 | 95.2 | | |
| Meningitis B M14113 Ab (N=244,42) | 28.3 | 100 | | |
| Meningitis B M08389 Ab (N=258,45) | 1.9 | 86.7 | | |
| Meningitis B M16822 Ab (N=240,34) | 85 | 100 | | |
| Meningitis B M10995 Ab (N=282,47) | 16.3 | 85.1 | | |
| Meningitis B M08780 Ab (N=241,40) | 0.8 | 92.5 | | |
| Meningitis B M09910 Ab (N=256,43) | 1.2 | 93 | | |
| Meningitis B M08320 Ab (N=277,45) | 45.1 | 86.8 | | |
| Meningitis B M14879 Ab (N=252,47) | 3.3 | 23.2 | | |
| Meningitis B M09345 Ab (N=263,48) | 32.3 | 74.9 | | |

| | | | | |
|-----------------------------------|------|------|--|--|
| Meningitis B M14594 Ab (N=254,44) | 35.8 | 97.7 | | |
| Meningitis B M07621 Ab (N=259,40) | 0.4 | 77.5 | | |
| Meningitis B M13568 Ab (N=268,40) | 9.7 | 95 | | |
| Meningitis B M18017 Ab (N=262,31) | 0 | 96.8 | | |
| Meningitis B M08420 Ab (N=260,40) | 0.8 | 95 | | |
| Meningitis B M07959 Ab (N=243,35) | 1.2 | 97.1 | | |
| Meningitis B M06970 Ab (N=243,32) | 28.8 | 90.6 | | |
| Meningitis B M10491 Ab (N=254,39) | 16.1 | 82.1 | | |
| Meningitis B M13569 Ab (N=233,31) | 0.4 | 96.8 | | |
| Meningitis B M10182 Ab (N=251,44) | 0 | 0 | | |
| Meningitis B M13547 Ab (N=260,44) | 5 | 47.7 | | |
| Meningitis B M15276 Ab (N=238,41) | 0.4 | 87.8 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination schedule for the MenB_0_2_6 group [3 dose], MenB_0_6 group and last MenABCWY dose (pooled lots)

| | |
|-----------------|--|
| End point title | Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination schedule for the MenB_0_2_6 group [3 dose], MenB_0_6 group and last MenABCWY dose (pooled lots) ^[44] |
|-----------------|--|

End point description:

The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the percentage of serogroup B invasive disease strains killed within a subject using enc-hSBA of the rMenB+OMV and MenABCWY vaccines.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | |
|-----------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 790 | 813 | 817 | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| >=50% killed strains | 98.7 (97.7 to 99.4) | 98.5 (97.4 to 99.2) | 98 (96.8 to 98.9) | |
| >=55% killed strains | 98.4 (97.2 to 99.1) | 97.4 (96.1 to 98.4) | 96.8 (95.4 to 97.9) | |

| | | | | |
|----------------------|---------------------|---------------------|---------------------|--|
| >=60% killed strains | 97.8 (96.6 to 98.7) | 96.8 (95.3 to 97.9) | 95.2 (93.5 to 96.6) | |
| >=65% killed strains | 96.5 (94.9 to 97.6) | 93.6 (91.7 to 95.2) | 90.1 (87.8 to 92) | |
| >=70% killed strains | 93.4 (91.5 to 95) | 89.8 (87.5 to 91.8) | 84.1 (81.4 to 86.5) | |
| >=75% killed strains | 86.8 (84.3 to 89.1) | 82.2 (79.4 to 84.7) | 74.7 (71.5 to 77.6) | |
| >=80% killed strains | 79.2 (76.2 to 82) | 75.5 (72.4 to 78.4) | 66 (62.6 to 69.2) | |
| >=85% killed strains | 62.8 (59.3 to 66.2) | 60.4 (56.9 to 63.8) | 50.1 (46.6 to 53.5) | |
| >=90% killed strains | 43.7 (40.2 to 47.2) | 41.3 (37.9 to 44.8) | 32.1 (28.9 to 35.4) | |
| >=95% killed strains | 22.5 (19.7 to 25.6) | 21 (18.3 to 24) | 13.7 (11.4 to 16.3) | |
| 100% killed strains | 10 (8 to 12.3) | 8.4 (6.6 to 10.5) | 6.1 (4.6 to 8) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

| | |
|-----------------|---|
| End point title | Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination with rMenB+OMV NZ (0,2-months) ^[45] |
|-----------------|---|

End point description:

The percentage of participants are classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (Day 91 for MenB_0_2_6 group [2 dose schedule])

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the percentage of serogroup B invasive disease strains killed within a subject using enc-hSBA of the rMenB+OMV vaccine.

| End point values | MenB_0_2_6 Group | | | |
|-----------------------------------|---------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 831 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| >=50% killed strains | 98.6 (97.5 to 99.3) | | | |
| >=55% killed strains | 97.7 (96.5 to 98.6) | | | |
| >=60% killed strains | 96.5 (95 to 97.7) | | | |

| | | | | |
|----------------------|---------------------|--|--|--|
| >=65% killed strains | 92.2 (90.1 to 93.9) | | | |
| >=70% killed strains | 84.8 (82.2 to 87.2) | | | |
| >=75% killed strains | 75.7 (72.6 to 78.6) | | | |
| >=80% killed strains | 66.7 (63.3 to 69.9) | | | |
| >=85% killed strains | 49.7 (46.2 to 53.2) | | | |
| >=90% killed strains | 33.8 (30.6 to 37.1) | | | |
| >=95% killed strains | 16.2 (13.8 to 18.9) | | | |
| 100% killed strains | 7.7 (6 to 9.7) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

| | |
|-----------------|--|
| End point title | Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots) ^[46] |
|-----------------|--|

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | |
|---|------------------|-----------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 749 | 731 | 780 | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| fHbp (M14459) Ab, Day 1 (N=749,730,762) | 4.9 (3.5 to 6.7) | 3.4 (2.2 to 5) | 5.4 (3.9 to 7.2) | |

| | | | | |
|--|---------------------|---------------------|---------------------|--|
| fHbp (M14459) Ab, Day 211 (N=690,707,738) | 97.4 (95.9 to 98.4) | 94.6 (92.7 to 96.2) | 95.9 (94.2 to 97.2) | |
| NadA (96217) Ab, Day 1 (N=744,731,780) | 6.2 (4.6 to 8.2) | 4.4 (3.0 to 6.1) | 6.2 (4.6 to 8.1) | |
| NadA (96217) Ab, Day 211 (N=691,707,734) | 100 (99.5 to 100) | 98 (96.7 to 98.9) | 96.2 (94.5 to 97.5) | |
| NHBA (M13520) Ab, Day 1 (N=749,731,764) | 23.2 (20.3 to 26.4) | 20.9 (18 to 24.1) | 18.5 (15.8 to 21.4) | |
| NHBA (M13520) Ab, Day 211 (N=695,711,738) | 97.0 (95.4 to 98.1) | 97.5 (96.0 to 98.5) | 95.3 (93.5 to 96.7) | |
| PorA (NZ98/254) Ab, Day 1 (N=738,716,751) | 2.3 (1.3 to 3.7) | 1.4 (0.7 to 2.6) | 2.1 (1.2 to 3.4) | |
| PorA (NZ98/254) Ab, Day 211 (N=657,684,709) | 85.8 (82.9 to 88.4) | 82.6 (79.5 to 85.4) | 75.3 (72.0 to 78.5) | |
| Composite Response, Day=1 (N=727,708,747) | 1.1 (0.5 to 2.2) | 0.6 (0.2 to 1.4) | 1.1 (0.5 to 2.1) | |
| Composite Response, Day=211 (N=654,683,707) | 83.3 (80.3 to 86.1) | 80.7 (77.5 to 83.6) | 71.4 (67.9 to 74.7) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers \geq LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

| | |
|-----------------|---|
| End point title | Percentage of participants with hSBA titers \geq LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months) ^[47] |
|-----------------|---|

End point description:

The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1 (pre-vaccination) and 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2 dose schedule])

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccine against N. meningitidis serogroup B indicator strain.

| | | | | |
|-----------------------------------|---------------------|--|--|--|
| End point values | MenB_0_2_6 Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 753 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| fHbp (M14459) Ab, Day 1 (N=749) | 4.9 (3.5 to 6.7) | | | |
| fHbp (M14459) Ab, Day 91 (N=750) | 92.9 (90.9 to 94.7) | | | |
| NadA (96217) Ab, Day 1 (N=744) | 6.2 (4.6 to 8.2) | | | |

| | | | | |
|--------------------------------------|---------------------|--|--|--|
| NadA (96217) Ab, Day 91 (N=753) | 99.5 (98.6 to 99.9) | | | |
| NHBA (M13520) Ab, Day 1 (N=749) | 23.2 (20.3 to 26.4) | | | |
| NHBA (M13520) Ab, Day 91 (N=750) | 96.1 (94.5 to 97.4) | | | |
| PorA N (NZ98/254) Ab, Day 1 (N=738) | 2.3 (1.3 to 3.7) | | | |
| PorA N (NZ98/254) Ab, Day 91 (N=745) | 80 (76.9 to 82.8) | | | |
| Composite Response, Day=1 (N=727) | 1.1 (0.5 to 2.2) | | | |
| Composite Response, Day=91 (N=744) | 75.5 (72.3 to 78.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

| | |
|-----------------|---|
| End point title | Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots) ^[48] |
|-----------------|---|

End point description:

The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥ 16 for subjects with a pre-vaccination hSBA titre < 4 a post-vaccination hSBA titer ≥ 4 times the LLOQ for subjects with a pre-vaccination hSBA titre $\geq \text{LOD}$ and $< \text{LLOQ}$ a post-vaccination hSBA titre ≥ 4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre $\geq \text{LLOQ}$. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | |
|-----------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 685 | 704 | 731 ^[49] | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| fHbp (M14459) Ab (N=679,699, 729) | 86.7 (84.0 to 89.2) | 82.4 (79.4 to 85.2) | 78.9 (75.7 to 81.8) | |
| NadA (96217) Ab (N=679,700,725) | 98.7 (97.5 to 99.4) | 95.3 (93.4 to 96.7) | 92.3 (90.1 to 94.1) | |

| | | | | |
|------------------------------------|---------------------|---------------------|---------------------|--|
| NHBA (M13520) Ab (N=685,704,731) | 66.9 (63.2 to 70.4) | 69.5 (65.9 to 72.8) | 61.1 (57.5 to 64.7) | |
| PorA (NZ98/254) Ab (N=637,664,693) | 56.5 (52.6 to 60.4) | 57.2 (53.4 to 61.0) | 42.4 (38.7 to 46.2) | |

Notes:

[49] - Analysis of final results for the ABCWY group is ongoing and will be updated subsequently.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2 months)

| | |
|-----------------|--|
| End point title | Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2 months) ^[50] |
|-----------------|--|

End point description:

The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥ 16 for participants with a pre-vaccination hSBA titre < 4 a post-vaccination hSBA titre ≥ 4 times the LLOQ for subjects with a pre-vaccination hSBA titre $\geq \text{LOD}$ and $< \text{LLOQ}$ a post-vaccination hSBA titre ≥ 4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre $\geq \text{LLOQ}$. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 [2-dose schedule]) compared to Day 1 (baseline)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccines against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | | | |
|-----------------------------------|---------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 739 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| fHbp (M14459) Ab (N=739) | 74.6 (71.3 to 77.7) | | | |
| NadA (96217) Ab (N=738) | 96.3 (94.7 to 97.6) | | | |
| NHBA (M13520) Ab (N=739) | 58.5 (54.8 to 62.0) | | | |
| PorA (NZ98/254) Ab (N=724) | 53.5 (49.7 to 57.1) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA Geometric Mean Titres (GMTs) against each of the N. meningitidis

serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

| | |
|-----------------|--|
| End point title | hSBA Geometric Mean Titres (GMTs) against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots) ^[51] |
|-----------------|--|

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | |
|---|----------------------|------------------------|------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 749 | 731 | 780 | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| fHbp (M14459) Ab, Day 1 (N=749,730,762) | 2.8 (2.7 to 2.8) | 2.7 (2.6 to 2.8) | 2.8 (2.7 to 2.9) | |
| fHbp (M14459) Ab, Day 211 (N=690,707,738) | 30.8 (28.3 to 33.5) | 28.1 (25.9 to 30.6) | 25 (23 to 27.1) | |
| NadA (96217) Ab, Day 1 (N=744,731,780) | 8.4 (8.1 to 8.6) | 8.3 (8 to 8.6) | 8.5 (8.2 to 8.8) | |
| NadA (96217) Ab, Day 211 (N=691,707,734) | 267.2 (243.7 to 293) | 215.1 (196.2 to 235.9) | 150.6 (137.3 to 165.2) | |
| NHBA (M13520) Ab, Day 1 (N=749,731,764) | 3.4 (3.1 to 3.7) | 3.2 (3 to 3.5) | 3.1 (2.8 to 3.4) | |
| NHBA (M13520) Ab, Day 211 (N=695,711,738) | 30.6 (27.7 to 33.7) | 33.2 (30.2 to 36.6) | 25.2 (22.9 to 27.8) | |
| PorA (NZ98/254) Ab, Day 1 (N=738,716,751) | 3.2 (3.1 to 3.2) | 3.1 (3 to 3.2) | 3.1 (3.1 to 3.2) | |
| PorA (NZ98/254) Ab, Day 211 (N=657,684,709) | 18.1 (16.3 to 20.1) | 17.7 (15.9 to 19.6) | 12.9 (11.6 to 14.4) | |

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMTs against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

| | |
|-----------------|--|
| End point title | hSBA GMTs against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months) ^[52] |
|-----------------|--|

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule])

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccine against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | | | |
|--|------------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 753 | | | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| fHbp (M14459) Ab, Day 1(N=749) | 2.8 (2.7 to 2.8) | | | |
| fHbp (M14459) Ab, Day 91(N=750) | 20.9 (18.9 to 23.1) | | | |
| NadA (96217) Ab, Day 1(N=744) | 8.4 (8.1 to 8.6) | | | |
| NadA (96217) Ab, Day 91(N=753) | 178.5 (161.7 to 197.2) | | | |
| NHBA (M13520) Ab, Day 1(N=749) | 3.4 (3.1 to 3.7) | | | |
| NHBA (M13520) Ab, Day 91(N=750) | 27.2 (24.1 to 30.6) | | | |
| PorA (NZ98/254) Ab, Day 1(N=738) | 3.2 (3.1 to 3.2) | | | |
| PorA (NZ98/254) Ab, Day 91(N=745) | 17.1 (15.2 to 19.3) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA Geometric Mean Ratios (GMRs) for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

| | |
|-----------------|---|
| End point title | hSBA Geometric Mean Ratios (GMRs) for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots) ^[53] |
|-----------------|---|

End point description:

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with

their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline) | |

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

| End point values | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | |
|--|---------------------|---------------------|-------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 685 | 704 | 731 | |
| Units: Ratio | | | | |
| geometric mean (confidence interval 95%) | | | | |
| fHbp (M14459) Ab (N=679,699,729) | 11.2 (10.3 to 12.2) | 10.5 (9.6 to 11.4) | 9 (8.2 to 9.8) | |
| NadA (96217) Ab (N=679,700,725) | 32.1 (29.1 to 35.3) | 25.8 (23.5 to 28.4) | 17.7 (16 to 19.4) | |
| NHBA (M13520) Ab (N=685,704,731) | 9.1 (8.2 to 10.1) | 10.6 (9.5 to 11.7) | 8.2 (7.4 to 9.1) | |
| PorA (NZ98/254) Ab (N=637,664,693) | 5.8 (5.2 to 6.5) | 5.8 (5.2 to 6.4) | 4.1 (3.7 to 4.6) | |

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMRs for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

| | |
|-----------------|---|
| End point title | hSBA GMRs for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2-months) ^[54] |
|-----------------|---|

End point description:

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. Analysis was performed on the FAS.

| | |
|--|-----------|
| End point type | Secondary |
| End point timeframe: | |
| At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule]) compared to Day 1 (baseline) | |

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccines against N. meningitidis serogroup B indicator strains.

| | | | | |
|--|-------------------|--|--|--|
| End point values | MenB_0_2_6 Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 739 | | | |
| Units: Ratio | | | | |
| geometric mean (confidence interval 95%) | | | | |
| fHbp (M14459) Ab (N=739) | 7.7 (6.9 to 8.5) | | | |
| NadA (96217) Ab (N=738) | 21.7 (19.5 to 24) | | | |
| NHBA (M13520) Ab (N=739) | 8 (7.1 to 9) | | | |
| PorA (NZ98/254) Ab (N=724) | 5.5 (4.9 to 6.2) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers \geq LLOQ for each of the N. meningitidis serogroups A,C,W,Y at Day 1 and at 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccine for ACWY group

| | |
|-----------------|--|
| End point title | Percentage of participants with hSBA titers \geq LLOQ for each of the N. meningitidis serogroups A,C,W,Y at Day 1 and at 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccine for ACWY group ^[55] |
|-----------------|--|

End point description:

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers \geq LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose])

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

| | | | | |
|-----------------------------------|---------------------|------------------------|--|--|
| End point values | ABCWY_Pooled | ACWY Group | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1489 | 141 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Men A, Day 1 (N=1452, 137) | 9.2 (7.7 to 10.8) | 11.7 (6.8 to 18.3) | | |
| Men A, Day 31 (N=132, 133) | 79.5 (71.7 to 86.1) | 90.2 (83.9 to 94.7) | | |
| Men A, Day 211 (N=1446) | 98.6 (97.9 to 99.2) | 99999 (99999 to 99999) | | |

| | | | | |
|----------------------------|---------------------|------------------------|--|--|
| Men C, Day 1 (N=1487, 139) | 29.8 (27.5 to 32.2) | 28.8 (21.4 to 37.1) | | |
| Men C, Day 31 (N=139,136) | 74.8 (66.8 to 81.8) | 64.0 (55.3 to 72.0) | | |
| Men C, Day 211 (N=1457) | 99.6 (99.1 to 99.8) | 99999 (99999 to 99999) | | |
| Men W, Day 1 (N=1473,140) | 12.6 (10.9 to 14.4) | 12.9 (7.8 to 19.6) | | |
| Men W, Day 31 (N=142,137) | 80.3 (72.8 to 86.5) | 69.3 (60.9 to 76.9) | | |
| Men W, Day 211 (N=1463) | 99.2 (98.7 to 99.6) | 99999 (99999 to 99999) | | |
| Men Y, Day 1 (N=1489,141) | 12.2 (10.6 to 14.0) | 13.5 (8.3 to 20.2) | | |
| Men Y, Day 91 (N=146,140) | 82.2 (75.0 to 88.0) | 80.0 (72.4 to 86.3) | | |
| Men Y, Day 211 (N=1461) | 99.2 (98.7 to 99.6) | 99999 (99999 to 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first MenABCWY dose for ABCWY_Pooled group compared to the MenACWY vaccine for ACWY group relative to baseline (Day 1)

| | |
|-----------------|---|
| End point title | Percentage of participants with 4-fold rise in hSBA titers for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first MenABCWY dose for ABCWY_Pooled group compared to the MenACWY vaccine for ACWY group relative to baseline (Day 1) ^[56] |
|-----------------|---|

End point description:

The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is < 4, then post-vaccination hSBA titer should be ≥ 16 . - If the pre-vaccination hSBA titer is \geq LOD but < LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is \geq LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled group] and for ACWY Group) relative to baseline (Day 1)

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

| End point values | ABCWY_Pooled | ACWY Group | | |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 146 | 140 | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | | | | |
| Men A (N=127,129) | 74.0 (65.5 to 81.4) | 86.0 (78.8 to 91.5) | | |
| Men C (N=139,134) | 66.9 (58.4 to 74.6) | 56.7 (47.9 to 65.2) | | |
| Men W (N=139,136) | 74.1 (66.0 to 81.2) | 66.2 (57.6 to 74.1) | | |
| Men Y (N=146,140) | 76.0 (68.3 to 82.7) | 72.1 (63.9 to 79.4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for the ABCWY_Pooled group and at 1 month after the MenACWY vaccination for ACWY Group

| | |
|-----------------|--|
| End point title | hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for the ABCWY_Pooled group and at 1 month after the MenACWY vaccination for ACWY Group ^[57] |
|-----------------|--|

End point description:

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose])

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

| End point values | ABCWY_Pooled | ACWY Group | | |
|--|------------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1489 | 141 | | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Men A, Day 1 (N=1452,137) | 11.1 (10.3 to 11.9) | 12.7 (10.9 to 14.8) | | |
| Men A, Day 31 (N=132,133) | 175.3 (121.2 to 253.3) | 474.8 (331.3 to 680.3) | | |

| | | | | |
|---------------------------|---------------------------|------------------------|--|--|
| Men A, Day 211 (N=1446) | 352.0 (322.0 to 384.7) | 99999 (99999 to 99999) | | |
| Men C, Day 1 (N=1487,139) | 12.0 (10.9 to 13.3) | 11.4 (9.1 to 14.3) | | |
| Men C, Day 31 (N=139,136) | 674.8 (355.9 to 1279.4) | 379.0 (204.4 to 703.0) | | |
| Men C, Day 211 (N=1457) | 1162.5 (1015.7 to 1330.5) | 99999 (99999 to 99999) | | |
| Men W, Day 1 (N=1473,140) | 8.0 (7.4 to 8.7) | 7.4 (6.2 to 8.9) | | |
| Men W, Day 31 (N=142,137) | 374.0 (243.4 to 574.8) | 194.3 (128.3 to 294.2) | | |
| Men W, Day 211 (N=1463) | 666.5 (603.2 to 736.3) | 99999 (99999 to 99999) | | |
| Men Y, Day 1 (N=1489,141) | 9.3 (8.7 to 10.0) | 9.9 (8.6 to 11.5) | | |
| Men Y, Day 31 (N=146,140) | 375.4 (246.9 to 570.7) | 320.9 (213.8 to 481.7) | | |
| Men Y, Day 211 (N=1461) | 655.9 (587.0 to 733.0) | 99999 (99999 to 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: GMRs for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first and the last MenABCWY vaccination for the ABCWY _Pooled group and at 1 month after the MenACWY vaccination for ACWY Group

| | |
|-----------------|--|
| End point title | GMRs for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first and the last MenABCWY vaccination for the ABCWY _Pooled group and at 1 month after the MenACWY vaccination for ACWY Group ^[58] |
|-----------------|--|

End point description:

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose]) compared to baseline (Day 1)

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY against N. meningitidis serogroups A, C, W, and Y.

| End point values | ABCWY_Pooled | ACWY Group | | |
|--|----------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 1446 | 140 | | |
| Units: Ratio | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Men A, Day 31 (N=127,129) | 11.8 (7.9 to 17.7) | 31.8 (21.4 to 47.1) | | |
| Men A, Day 211 (N=1397) | 31.2 (28.3 to 34.5) | 99999 (99999 to 99999) | | |
| Men C, Day 31 (N=139,134) | 30.9 (16.9 to 56.2) | 22.9 (12.8 to 41.1) | | |
| Men C, Day 211 (N=1439) | 96.9 (84.5 to 111.1) | 99999 (99999 to 99999) | | |
| Men W, Day 31 (N=139,136) | 32.9 (21.7 to 50.0) | 23.2 (15.5 to 34.7) | | |
| Men W, Day 211 (N=1432) | 83.8 (74.9 to 93.8) | 99999 (99999 to 99999) | | |
| Men Y, Day 31 (N=146,140) | 28.1 (18.3 to 43.2) | 25.6 (16.9 to 38.8) | | |
| Men Y, Day 211 (N=1446) | 70.2 (62.3 to 79.1) | 99999 (99999 to 99999) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Total Immunoglobulin G (IgG) antibodies concentrations against N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccination for ACWY Group

| | |
|-----------------|--|
| End point title | Total Immunoglobulin G (IgG) antibodies concentrations against N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccination for ACWY Group ^[59] |
|-----------------|--|

End point description:

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (EGL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). EGL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

| End point values | ABCWY_Pooled | ACWY Group | | |
|--|---------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 179 | 172 | | |
| Units: microgram per milliliter(µg/mL) | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Men A, Day 1 (N=170, 179) | 1.9 (1.6 to 2.2) | 2.3 (2.0 to 2.7) | | |
| Men A, Day 31 (N=168, 177) | 18.1 (13.8 to 23.8) | 53.7 (40.8 to 70.7) | | |
| Men A, Day 211 (N=164) | 30.2 (23.3 to 39.2) | 99999 (99999 to 99999) | | |
| Men C, Day 1 (N=170, 179) | 0.7 (0.6 to 0.8) | 0.8 (0.7 to 1.0) | | |
| Men C, Day 31 (N=170, 175) | 15.5 (11.6 to 20.7) | 13.8 (10.4 to 18.4) | | |
| Men C, Day 211 (N=163) | 17.0 (13.1 to 22.0) | 99999 (99999 to 99999) | | |
| Men W, Day 1 (N=170, 179) | 0.5 (0.4 to 0.6) | 0.6 (0.5 to 0.7) | | |
| Men W, Day 31 (N=172, 178) | 9.1 (6.5 to 12.8) | 8.4 (6.0 to 11.6) | | |
| Men W, Day 211 (N=164) | 21.7 (16.0 to 29.5) | 99999 (99999 to 99999) | | |
| Men Y, Day 1 (N=170, 179) | 0.9 (0.7 to 1.0) | 0.9 (0.8 to 1.0) | | |
| Men Y, Day 31 (N=172, 178) | 12.9 (9.2 to 18.0) | 14.3 (10.2 to 19.8) | | |
| Men Y, Day 211 (N=164) | 26.3 (19.6 to 35.4) | 99999 (99999 to 99999) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

SAEs and Non-serious AEs (Other AEs) were collected through the entire period of the study (from Day 1 up to study end [Day 361])

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|--------------------|--------|
| Dictionary name | MedDRA |
| Dictionary version | 25.0 |

Reporting groups

| | |
|-----------------------|------------------|
| Reporting group title | MenB_0_2_6 Group |
|-----------------------|------------------|

Reporting group description:

Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.

| | |
|-----------------------|--------------|
| Reporting group title | ABCWY_Pooled |
|-----------------------|--------------|

Reporting group description:

Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

| | |
|-----------------------|------------|
| Reporting group title | ACWY Group |
|-----------------------|------------|

Reporting group description:

Participants received 1 dose of MenACWY vaccine at Day 1, 1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.

| | |
|-----------------------|----------------|
| Reporting group title | MenB_0_6 Group |
|-----------------------|----------------|

Reporting group description:

Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.

| Serious adverse events | MenB_0_2_6 Group | ABCWY_Pooled | ACWY Group |
|---|------------------|-------------------|-----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 20 / 897 (2.23%) | 25 / 1657 (1.51%) | 5 / 178 (2.81%) |
| number of deaths (all causes) | 1 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Testis cancer | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain stem glioma | | | |

| | | | |
|--|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian fibroma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion spontaneous | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Complication of pregnancy | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Placental insufficiency | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pre-eclampsia | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Anaphylactic reaction | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Ovarian cyst ruptured | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depression | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Suicide attempt | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Substance-induced psychotic disorder | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Major depression | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depression suicidal | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anorexia nervosa | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychotic disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thinking abnormal | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Troponin T increased | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Concussion | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Road traffic accident | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|------------------|-----------------|
| Post procedural haemorrhage subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Poisoning subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Overdose subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower limb fracture subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intentional overdose subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxicity to various agents subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ulna fracture subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Traumatic liver injury subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neck injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain contusion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skull fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Urachal abnormality | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aphasia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorder | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paresis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Petit mal epilepsy | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Speech disorder | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuromyelitis optica spectrum disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |
| Hypermetropia | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|------------------|-----------------|
| Nausea | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatitis toxic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Excessive granulation tissue | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vancomycin infusion reaction | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urethral stenosis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Intervertebral disc protrusion | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post-acute COVID-19 syndrome | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngeal abscess | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected dermal cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | MenB_0_6 Group | | |
|---|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 22 / 906 (2.43%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Testis cancer | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain stem glioma | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ovarian fibroma | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pregnancy, puerperium and perinatal conditions | | | |
| Abortion spontaneous | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Complication of pregnancy | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Placental insufficiency | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pre-eclampsia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Anaphylactic reaction | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Ovarian cyst ruptured | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Depression | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Suicide attempt | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 906 (0.22%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Substance-induced psychotic disorder | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Major depression | | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Depression suicidal | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Mental disorder | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anorexia nervosa | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Suicidal ideation | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Psychotic disorder | | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thinking abnormal | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Troponin T increased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Concussion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tendon rupture | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|--|-----------------|--|--|--|
| Post procedural haemorrhage subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Poisoning subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Overdose subjects affected / exposed | 1 / 906 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Lower limb fracture subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intentional overdose subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Toxicity to various agents subjects affected / exposed | 1 / 906 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ulna fracture subjects affected / exposed | 0 / 906 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Traumatic liver injury subjects affected / exposed | 1 / 906 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Injury | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Back injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neck injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Head injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain contusion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skull fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Congenital, familial and genetic disorders | | | |
| Urachal abnormality | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Dysarthria | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aphasia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Headache | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Paresis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Petit mal epilepsy | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Speech disorder | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Subarachnoid haemorrhage | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neuromyelitis optica spectrum disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eye disorders | | | |
| Hypermetropia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|-----------------|--|--|
| Nausea | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatitis toxic | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Excessive granulation tissue | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vancomycin infusion reaction | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Intervertebral disc protrusion | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tooth abscess | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Post-acute COVID-19 syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pharyngeal abscess | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infected dermal cyst | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | MenB_0_2_6 Group | ABCWY_Pooled | ACWY Group |
|---|--------------------|----------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 876 / 897 (97.66%) | 1599 / 1657 (96.50%) | 173 / 178 (97.19%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin papilloma | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Benign soft tissue neoplasm | | | |

| | | | |
|---|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Fibroadenoma of breast subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Lipoma subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Melanocytic naevus subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Vascular disorders | | | |
| Pallor subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Hypertension subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 1 / 178 (0.56%) 1 |
| Hot flush subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Varicose vein subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Hypotension subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Hyperaemia subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Peripheral venous disease subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |

| | | | |
|--|----------------------------|---------------------------------|---------------------------|
| Orthostatic hypotension subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Induration subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Administration site erythema subjects affected / exposed occurrences (all) | 209 / 897 (23.30%) 300 | 321 / 1657 (19.37%) 397 | 21 / 178 (11.80%) 24 |
| Administration site induration subjects affected / exposed occurrences (all) | 138 / 897 (15.38%) 180 | 223 / 1657 (13.46%) 273 | 17 / 178 (9.55%) 19 |
| Administration site pain subjects affected / exposed occurrences (all) | 851 / 897 (94.87%) 2229 | 1561 / 1657 (94.21%) 3056 | 149 / 178 (83.71%) 240 |
| Administration site swelling subjects affected / exposed occurrences (all) | 202 / 897 (22.52%) 293 | 305 / 1657 (18.41%) 401 | 22 / 178 (12.36%) 25 |
| Asthenia subjects affected / exposed occurrences (all) | 2 / 897 (0.22%) 2 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Chest pain subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 3 / 1657 (0.18%) 3 | 1 / 178 (0.56%) 1 |
| Chills subjects affected / exposed occurrences (all) | 8 / 897 (0.89%) 8 | 6 / 1657 (0.36%) 6 | 0 / 178 (0.00%) 0 |
| Cyst subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Fatigue subjects affected / exposed occurrences (all) | 604 / 897 (67.34%) 1183 | 1066 / 1657 (64.33%) 1807 | 105 / 178 (58.99%) 174 |
| Feeling hot | | | |

| | | | |
|------------------------------|-----------------|-------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 3 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Thirst | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site haematoma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site hypoaesthesia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site induration | | | |
| subjects affected / exposed | 8 / 897 (0.89%) | 13 / 1657 (0.78%) | 2 / 178 (1.12%) |
| occurrences (all) | 11 | 14 | 2 |
| Injection site mass | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Injection site pain | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 13 / 1657 (0.78%) | 1 / 178 (0.56%) |
| occurrences (all) | 3 | 13 | 1 |
| Injection site pruritus | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 5 / 1657 (0.30%) | 1 / 178 (0.56%) |
| occurrences (all) | 4 | 6 | 1 |
| Injection site rash | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Injection site swelling | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site warmth | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 3 | 0 |
| Malaise | | | |

| | | | |
|-----------------------------|------------------|--------------------|-----------------|
| subjects affected / exposed | 4 / 897 (0.45%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 3 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Pain | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 4 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 66 / 897 (7.36%) | 115 / 1657 (6.94%) | 7 / 178 (3.93%) |
| occurrences (all) | 69 | 122 | 7 |
| Swelling | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Injection site bruising | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Vaccination site pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaccination site urticaria | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vaccination site warmth | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vessel puncture site pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaccination site pruritus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Medical device pain | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Discomfort | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site discomfort | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site eczema | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site erythema | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site papule | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site paraesthesia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oedema peripheral | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vaccination site bruising | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vaccination site erythema | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vaccination site reaction | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Swelling face | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Immune system disorders | | | |
| Anaphylactoid reaction | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Food allergy | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Multiple allergies | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Seasonal allergy | | | |
| subjects affected / exposed | 7 / 897 (0.78%) | 9 / 1657 (0.54%) | 2 / 178 (1.12%) |
| occurrences (all) | 7 | 9 | 2 |
| Allergy to animal | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|--|------------------------|-------------------------|----------------------|
| Allergy to arthropod sting subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Dust allergy subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Social circumstances Menarche subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Reproductive system and breast disorders | | | |
| Heavy menstrual bleeding subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Breast cyst subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Breast inflammation subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Breast mass subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Breast tenderness subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Dysmenorrhoea subjects affected / exposed occurrences (all) | 14 / 897 (1.56%) 19 | 25 / 1657 (1.51%) 31 | 6 / 178 (3.37%) 6 |
| Endometriosis subjects affected / exposed occurrences (all) | 2 / 897 (0.22%) 2 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Nipple enlargement | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Penile rash | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Premenstrual syndrome | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Testicular pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Menstruation irregular | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abnormal uterine bleeding | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Amenorrhoea | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bartholin's cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Breast discharge | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Breast haematoma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Breast pain | | | |

| | | | |
|---|------------------|-------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Menstruation delayed | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Premenstrual pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Uterine spasm | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 8 / 1657 (0.48%) | 2 / 178 (1.12%) |
| occurrences (all) | 4 | 8 | 2 |
| Asthma | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 2 | 0 |
| Cough | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 16 / 1657 (0.97%) | 3 / 178 (1.69%) |
| occurrences (all) | 4 | 16 | 3 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 4 | 1 |
| Nasal congestion | | | |
| subjects affected / exposed | 12 / 897 (1.34%) | 16 / 1657 (0.97%) | 0 / 178 (0.00%) |
| occurrences (all) | 13 | 18 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 12 / 897 (1.34%) | 29 / 1657 (1.75%) | 0 / 178 (0.00%) |
| occurrences (all) | 12 | 29 | 0 |
| Respiratory tract congestion | | | |

| | | | |
|----------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinalgia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 3 / 1657 (0.18%) | 1 / 178 (0.56%) |
| occurrences (all) | 2 | 3 | 1 |
| Sneezing | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillolith | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Increased upper airway secretion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Throat clearing | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hiccups | | | |

| | | | |
|--|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 11 / 1657 (0.66%) | 0 / 178 (0.00%) |
| occurrences (all) | 6 | 11 | 0 |
| Anorexia nervosa | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Aggression | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Adjustment disorder with depressed mood | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Adjustment disorder | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Anxiety disorder | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Depression suicidal | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Disruptive mood dysregulation disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Panic attack | | | |

| | | | |
|---------------------------------------|-----------------|-------------------|-----------------|
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Depression | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 14 / 1657 (0.84%) | 2 / 178 (1.12%) |
| occurrences (all) | 6 | 14 | 2 |
| Confusional state | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Binge eating | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 7 / 1657 (0.42%) | 1 / 178 (0.56%) |
| occurrences (all) | 3 | 7 | 1 |
| Stress | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Suicidal ideation | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Anger | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Acute stress disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Irritability | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mixed anxiety and depressive disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|----------------------|-----------------------|----------------------|
| Obsessive-compulsive disorder subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| School refusal subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Hallucination subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Investigations | | | |
| SARS-CoV-2 test positive subjects affected / exposed occurrences (all) | 6 / 897 (0.67%) 6 | 6 / 1657 (0.36%) 6 | 1 / 178 (0.56%) 1 |
| Body temperature increased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Cardiac murmur subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Computerised tomogram abdomen abnormal subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Haemoglobin decreased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Heart rate irregular subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Liver function test increased subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Serum ferritin decreased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Streptococcus test positive | | | |

| | | | |
|--|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Thyroid hormones decreased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 1 / 178 (0.56%) 1 |
| Blood pressure increased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Heart rate increased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Red blood cell count increased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Arthropod bite subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Arthropod sting subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Ankle fracture subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Clavicle fracture subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Ligament sprain | | | |

| | | | |
|-----------------------------|-----------------|-------------------|-----------------|
| subjects affected / exposed | 5 / 897 (0.56%) | 14 / 1657 (0.84%) | 1 / 178 (0.56%) |
| occurrences (all) | 7 | 14 | 1 |
| Contusion | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 8 / 1657 (0.48%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 12 | 0 |
| Eye abrasion | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye injury | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Facial bones fracture | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Fall | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 2 / 178 (1.12%) |
| occurrences (all) | 1 | 3 | 2 |
| Fibula fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Foot fracture | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Hand fracture | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 6 / 1657 (0.36%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 7 | 0 |
| Head injury | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 2 | 1 |
| Human bite | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infusion related reaction | | | |

| | | | |
|------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint dislocation | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 2 | 1 |
| Joint injury | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 4 | 4 | 0 |
| Ligament rupture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 2 | 1 |
| Concussion | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 5 | 0 |
| Limb injury | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 5 | 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 3 / 1657 (0.18%) | 2 / 178 (1.12%) |
| occurrences (all) | 3 | 3 | 2 |
| Meniscus injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle rupture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Musculoskeletal foreign body | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nail injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Post procedural complication | | | |

| | | | |
|------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Post-traumatic neck syndrome | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural complication | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural dizziness | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural nausea | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Procedural vomiting | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Radius fracture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 4 | 1 |
| Road traffic accident | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Scratch | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lower limb fracture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Skin laceration | | | |
| subjects affected / exposed | 5 / 897 (0.56%) | 5 / 1657 (0.30%) | 1 / 178 (0.56%) |
| occurrences (all) | 5 | 5 | 1 |
| Thermal burn | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Torus fracture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Traumatic haematoma | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 4 / 1657 (0.24%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 4 | 1 |
| Upper limb fracture | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Vaccination complication | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 2 | 0 | 1 |
| Wrist fracture | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 9 / 1657 (0.54%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 9 | 0 |
| Tendon injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Anaesthetic complication | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Animal bite | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Animal scratch | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tooth injury | | | |

| | | | |
|-----------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bursa injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Compression fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ear canal injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Foreign body in respiratory tract | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ligament injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Limb crushing injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Limb fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nasal injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Post procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Soft tissue injury | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sports injury | | | |

| | | | |
|--|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Stress fracture | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sunburn | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Bone contusion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Traumatic haemorrhage | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Wound | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Congenital, familial and genetic disorders | | | |
| Multiple endocrine neoplasia Type 1 | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rathke's cleft cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Type V hyperlipidaemia | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Familial mediterranean fever | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermoid cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pectus excavatum | | | |

| | | | |
|--|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia paroxysmal | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Nervous system disorders | | | |
| Dyskinesia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 7 / 1657 (0.42%) | 1 / 178 (0.56%) |
| occurrences (all) | 8 | 7 | 1 |
| Headache | | | |
| subjects affected / exposed | 578 / 897 (64.44%) | 929 / 1657 (56.07%) | 97 / 178 (54.49%) |
| occurrences (all) | 999 | 1578 | 148 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 11 / 1657 (0.66%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 11 | 1 |
| Speech disorder | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lethargy | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Migraine | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 4 | 0 |
| Myoclonus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuromuscular blockade | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Presyncope | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 5 | 0 |
| Psychomotor hyperactivity | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Seizure | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Carpal tunnel syndrome | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Paraesthesia | | | |

| | | | |
|--|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Sleep deficit subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Tension headache subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 3 / 1657 (0.18%) 4 | 0 / 178 (0.00%) 0 |
| Iron deficiency anaemia subjects affected / exposed occurrences (all) | 4 / 897 (0.45%) 4 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Lymphadenitis subjects affected / exposed occurrences (all) | 2 / 897 (0.22%) 2 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 5 / 897 (0.56%) 6 | 9 / 1657 (0.54%) 9 | 1 / 178 (0.56%) 1 |
| Coagulopathy subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Increased tendency to bruise subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Ear and labyrinth disorders | | | |
| Hypoacusis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Eustachian tube dysfunction subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Tympanic membrane perforation | | | |

| | | | |
|------------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vertigo | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 4 | 2 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cerumen impaction | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Ear discomfort | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ear pain | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 6 / 1657 (0.36%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 6 | 0 |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| External ear inflammation | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Motion sickness | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Tympanosclerosis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye disorders | | | |
| Astigmatism | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| Blepharitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Keratitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Swelling of eyelid | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eye irritation | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Conjunctivitis allergic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blindness transient | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye swelling | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Chalazion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|--|----------------------|-------------------------|----------------------|
| Eye inflammation subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Eye pruritus subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Eyelid exfoliation subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Eyelid ptosis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Myopia subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Abdominal distension subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Abdominal pain subjects affected / exposed occurrences (all) | 7 / 897 (0.78%) 7 | 13 / 1657 (0.78%) 17 | 1 / 178 (0.56%) 1 |
| Abdominal pain lower subjects affected / exposed occurrences (all) | 3 / 897 (0.33%) 3 | 2 / 1657 (0.12%) 2 | 1 / 178 (0.56%) 1 |
| Abdominal pain upper subjects affected / exposed occurrences (all) | 7 / 897 (0.78%) 7 | 18 / 1657 (1.09%) 20 | 2 / 178 (1.12%) 2 |
| Anal fissure subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Colitis | | | |

| | | | |
|----------------------------------|------------------|-------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 5 | 0 |
| Dental caries | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 14 / 897 (1.56%) | 13 / 1657 (0.78%) | 5 / 178 (2.81%) |
| occurrences (all) | 15 | 13 | 5 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 5 / 1657 (0.30%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 5 | 1 |
| Enteritis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Food poisoning | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 5 / 1657 (0.30%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 5 | 1 |
| Gastritis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperchlorhydria | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoaesthesia oral | | | |

| | | | |
|-----------------------------|--------------------|---------------------|-------------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip swelling | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Nausea | | | |
| subjects affected / exposed | 245 / 897 (27.31%) | 398 / 1657 (24.02%) | 45 / 178 (25.28%) |
| occurrences (all) | 324 | 500 | 59 |
| Oral pain | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pancreatitis relapsing | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peptic ulcer | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Toothache | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 7 / 1657 (0.42%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 7 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 12 / 1657 (0.72%) | 1 / 178 (0.56%) |
| occurrences (all) | 6 | 12 | 1 |
| Oral pruritus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|--|-----------------|-------------------|-----------------|
| Coeliac disease | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Embedded tooth | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Eructation | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Flatulence | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Palatal disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tongue discolouration | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Transient lingual papillitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatobiliary disorders | | | |
| Hepatic steatosis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Pityriasis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Acne | | | |
| subjects affected / exposed | 8 / 897 (0.89%) | 12 / 1657 (0.72%) | 1 / 178 (0.56%) |
| occurrences (all) | 8 | 14 | 1 |
| Cold urticaria | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dermatitis allergic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dermatitis atopic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Dermatitis contact | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 5 | 0 |
| Eczema | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 4 | 6 | 0 |
| Erythema | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Hand dermatitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Ingrowing nail | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Miliaria | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain of skin | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |

| | | | |
|-----------------------------|-----------------|-------------------|-----------------|
| subjects affected / exposed | 3 / 897 (0.33%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 13 / 1657 (0.78%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 13 | 0 |
| Rash macular | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Rash pruritic | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 4 / 1657 (0.24%) | 1 / 178 (0.56%) |
| occurrences (all) | 2 | 4 | 1 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nail disorder | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Rash erythematous | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin induration | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria chronic | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 5 | 0 |
| Haematuria | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nephritis | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Urinary tract inflammation | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|-----------------|------------------|-----------------|
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thyroid stimulating hormone deficiency | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Growth hormone deficiency | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Thyroid cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Joint swelling | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Growing pains | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Foot deformity | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Flank pain | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Epiphysiolysis | | | |

| | | | |
|-----------------------------|--------------------|---------------------|-------------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 7 / 897 (0.78%) | 15 / 1657 (0.91%) | 2 / 178 (1.12%) |
| occurrences (all) | 7 | 15 | 2 |
| Axillary mass | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Arthritis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Arthralgia | | | |
| subjects affected / exposed | 154 / 897 (17.17%) | 236 / 1657 (14.24%) | 25 / 178 (14.04%) |
| occurrences (all) | 205 | 290 | 30 |
| Joint warmth | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Knee deformity | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle swelling | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle tightness | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Joint hyperextension | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tenosynovitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Tendon pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------|--------------------|---------------------|-------------------|
| Temporomandibular joint syndrome | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Spinal pain | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Sever's disease | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 5 / 897 (0.56%) | 9 / 1657 (0.54%) | 1 / 178 (0.56%) |
| occurrences (all) | 5 | 12 | 1 |
| Osteochondrosis | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Neck mass | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myositis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 240 / 897 (26.76%) | 384 / 1657 (23.17%) | 30 / 178 (16.85%) |
| occurrences (all) | 325 | 500 | 35 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhabdomyolysis | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Joint effusion | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Myokymia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sacral pain | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Scoliosis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Short stature | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Spinal flattening | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Synovial cyst | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Tendonitis | | | |

| | | | |
|---|----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Torticollis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Infections and infestations | | | |
| Bacterial vaginosis subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Acarodermatitis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Acute sinusitis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 4 / 1657 (0.24%) 4 | 0 / 178 (0.00%) 0 |
| Adenovirus infection subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Asymptomatic COVID-19 subjects affected / exposed occurrences (all) | 3 / 897 (0.33%) 3 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Enterovirus infection subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Enterobiasis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Eye infection subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Eyelid infection subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 0 / 1657 (0.00%) 0 | 0 / 178 (0.00%) 0 |
| Folliculitis subjects affected / exposed occurrences (all) | 1 / 897 (0.11%) 1 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |

| | | | |
|-----------------------------|-------------------|---------------------|-------------------|
| Gastroenteritis | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 16 / 1657 (0.97%) | 0 / 178 (0.00%) |
| occurrences (all) | 6 | 16 | 0 |
| Body tinea | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 4 | 0 |
| Bullous impetigo | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| COVID-19 | | | |
| subjects affected / exposed | 93 / 897 (10.37%) | 195 / 1657 (11.77%) | 26 / 178 (14.61%) |
| occurrences (all) | 96 | 198 | 26 |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Chlamydial infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Coronavirus infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Cystitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 5 / 1657 (0.30%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 5 | 1 |
| Ear infection | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 2 / 1657 (0.12%) | 1 / 178 (0.56%) |
| occurrences (all) | 3 | 2 | 1 |
| Endometritis | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema migrans | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 7 / 1657 (0.42%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 7 | 0 |
| Genital herpes | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gingivitis | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Infected bite | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 3 | 1 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Impetigo | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 3 / 1657 (0.18%) | 2 / 178 (1.12%) |
| occurrences (all) | 2 | 3 | 2 |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 6 / 1657 (0.36%) | 1 / 178 (0.56%) |
| occurrences (all) | 2 | 6 | 1 |
| Localised infection | | | |

| | | | |
|-----------------------------------|------------------|-------------------|------------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lyme disease | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Mycoplasma genitalium infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 29 / 897 (3.23%) | 60 / 1657 (3.62%) | 11 / 178 (6.18%) |
| occurrences (all) | 33 | 65 | 11 |
| Onychomycosis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 10 / 1657 (0.60%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 10 | 0 |
| Otitis media | | | |
| subjects affected / exposed | 6 / 897 (0.67%) | 6 / 1657 (0.36%) | 0 / 178 (0.00%) |
| occurrences (all) | 6 | 6 | 0 |
| Otitis media acute | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 3 / 1657 (0.18%) | 1 / 178 (0.56%) |
| occurrences (all) | 4 | 3 | 1 |
| Otosalpingitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 5 / 1657 (0.30%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Parotitis | | | |

| | | | |
|---------------------------------------|------------------|-------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pelvic inflammatory disease | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 8 / 897 (0.89%) | 28 / 1657 (1.69%) | 2 / 178 (1.12%) |
| occurrences (all) | 9 | 30 | 2 |
| Influenza | | | |
| subjects affected / exposed | 10 / 897 (1.11%) | 22 / 1657 (1.33%) | 1 / 178 (0.56%) |
| occurrences (all) | 10 | 22 | 1 |
| Postoperative wound infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pulpitis dental | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 4 / 1657 (0.24%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Respiratory tract infection bacterial | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 11 / 1657 (0.66%) | 2 / 178 (1.12%) |
| occurrences (all) | 3 | 14 | 2 |
| Rhinitis | | | |
| subjects affected / exposed | 4 / 897 (0.45%) | 6 / 1657 (0.36%) | 2 / 178 (1.12%) |
| occurrences (all) | 4 | 6 | 2 |
| Rhinovirus infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sialoadenitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sinusitis | | | |

| | | | |
|-----------------------------|------------------|-------------------|-----------------|
| subjects affected / exposed | 4 / 897 (0.45%) | 3 / 1657 (0.18%) | 2 / 178 (1.12%) |
| occurrences (all) | 4 | 3 | 2 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Soft tissue infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Streptococcal infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Suspected COVID-19 | | | |
| subjects affected / exposed | 5 / 897 (0.56%) | 10 / 1657 (0.60%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 11 | 0 |
| Tinea versicolour | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 10 / 897 (1.11%) | 20 / 1657 (1.21%) | 5 / 178 (2.81%) |
| occurrences (all) | 10 | 22 | 6 |
| Tonsillitis streptococcal | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Tooth infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 2 / 1657 (0.12%) | 1 / 178 (0.56%) |
| occurrences (all) | 1 | 2 | 1 |
| Yersinia infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Tracheitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Trichomoniasis | | | |

| | | | |
|---|------------------|-------------------|-----------------|
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 35 / 897 (3.90%) | 71 / 1657 (4.28%) | 6 / 178 (3.37%) |
| occurrences (all) | 38 | 74 | 6 |
| Upper respiratory tract infection bacterial | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 9 / 897 (1.00%) | 13 / 1657 (0.78%) | 3 / 178 (1.69%) |
| occurrences (all) | 11 | 17 | 3 |
| Vaginal infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 1 | 2 |
| Varicella | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 5 / 897 (0.56%) | 7 / 1657 (0.42%) | 0 / 178 (0.00%) |
| occurrences (all) | 5 | 8 | 0 |
| Viral pharyngitis | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 897 (0.33%) | 9 / 1657 (0.54%) | 0 / 178 (0.00%) |
| occurrences (all) | 3 | 9 | 0 |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Vulvovaginal mycotic infection | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|----------------------------------|-----------------|------------------|-----------------|
| Laryngitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 9 / 1657 (0.54%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 9 | 0 |
| Conjunctivitis viral | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Ear lobe infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fungal foot infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Fungal skin infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal viral infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hand-foot-and-mouth disease | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Helminthic infection | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pericoronitis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Parasitic gastroenteritis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|----------------------|-----------------------|----------------------|
| Post-acute COVID-19 syndrome subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Respiratory syncytial virus infection subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Skin bacterial infection subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 3 / 1657 (0.18%) 3 | 0 / 178 (0.00%) 0 |
| Subcutaneous abscess subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Tinea pedis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Vaccination site cellulitis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Vaccination site pustule subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Vulvovaginitis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 2 / 1657 (0.12%) 2 | 0 / 178 (0.00%) 0 |
| Laryngotracheitis obstructive subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Molluscum contagiosum subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Oral candidiasis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |
| Pharyngotonsillitis subjects affected / exposed occurrences (all) | 0 / 897 (0.00%) 0 | 1 / 1657 (0.06%) 1 | 0 / 178 (0.00%) 0 |

| | | | |
|------------------------------------|-----------------|------------------|-----------------|
| Metabolism and nutrition disorders | | | |
| Insulin resistance | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 6 / 1657 (0.36%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 6 | 0 |
| Lactose intolerance | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Obesity | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin B complex deficiency | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vitamin B12 deficiency | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Abnormal loss of weight | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 2 / 1657 (0.12%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 2 / 897 (0.22%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gluten sensitivity | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 1 / 178 (0.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Hypercholesterolaemia | | | |

| | | | |
|-----------------------------|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 897 (0.11%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Zinc deficiency | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 1 / 897 (0.11%) | 0 / 1657 (0.00%) | 0 / 178 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 3 / 1657 (0.18%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Haemochromatosis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypovitaminosis | | | |
| subjects affected / exposed | 0 / 897 (0.00%) | 1 / 1657 (0.06%) | 0 / 178 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|--------------------|--|--|
| Non-serious adverse events | MenB_0_6 Group | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 872 / 906 (96.25%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Basal cell carcinoma | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Skin papilloma | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Benign soft tissue neoplasm | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fibroadenoma of breast | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Lipoma | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Melanocytic naevus | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vascular disorders | | | |
| Pallor | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hypertension | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hot flush | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Varicose vein | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|--|--------------------|--|--|
| Hyperaemia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Peripheral venous disease | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| General disorders and administration site conditions | | | |
| Induration | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Administration site erythema | | | |
| subjects affected / exposed | 157 / 906 (17.33%) | | |
| occurrences (all) | 203 | | |
| Administration site induration | | | |
| subjects affected / exposed | 113 / 906 (12.47%) | | |
| occurrences (all) | 142 | | |
| Administration site pain | | | |
| subjects affected / exposed | 853 / 906 (94.15%) | | |
| occurrences (all) | 1768 | | |
| Administration site swelling | | | |
| subjects affected / exposed | 158 / 906 (17.44%) | | |
| occurrences (all) | 200 | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Chest pain | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Chills | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 4 | | |
| Cyst | | | |

| | | | |
|------------------------------|--------------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Fatigue | | | |
| subjects affected / exposed | 579 / 906 (63.91%) | | |
| occurrences (all) | 1005 | | |
| Feeling hot | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 3 | | |
| Thirst | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site haematoma | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Injection site hypoaesthesia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Injection site induration | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 5 | | |
| Injection site mass | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Injection site pain | | | |
| subjects affected / exposed | 8 / 906 (0.88%) | | |
| occurrences (all) | 8 | | |
| Injection site pruritus | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 2 | | |
| Injection site rash | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Injection site swelling | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Injection site warmth | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Malaise | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 59 / 906 (6.51%) | | |
| occurrences (all) | 62 | | |
| Swelling | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vaccination site urticaria | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site warmth | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vessel puncture site pain | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Vaccination site pruritus | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Medical device pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Axillary pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Discomfort | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Feeling cold | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site discomfort | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site eczema | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site erythema | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site papule | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site paraesthesia | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site bruising | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site erythema | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site reaction | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Swelling face | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Immune system disorders | | | |
| Anaphylactoid reaction | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Food allergy | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Multiple allergies | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |

| | | | |
|--|------------------------|--|--|
| Seasonal allergy subjects affected / exposed occurrences (all) | 7 / 906 (0.77%) 7 | | |
| Allergy to animal subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Allergy to arthropod sting subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Dust allergy subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Social circumstances Menarche subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Breast cyst subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Breast inflammation subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Breast mass subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Breast tenderness subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Dysmenorrhoea subjects affected / exposed occurrences (all) | 10 / 906 (1.10%) 10 | | |
| Endometriosis | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Intermenstrual bleeding | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nipple enlargement | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Penile rash | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Premenstrual syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Testicular pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vaginal haemorrhage | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Menstruation irregular | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Abnormal uterine bleeding | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Amenorrhoea | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Bartholin's cyst | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Breast discharge | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Breast haematoma | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Breast pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Menstruation delayed | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Premenstrual pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Uterine spasm | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Asthma | | | |
| subjects affected / exposed | 6 / 906 (0.66%) | | |
| occurrences (all) | 8 | | |
| Cough | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 4 | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Epistaxis | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Nasal congestion | | | |

| | | | |
|----------------------------------|------------------|--|--|
| subjects affected / exposed | 6 / 906 (0.66%) | | |
| occurrences (all) | 6 | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 11 / 906 (1.21%) | | |
| occurrences (all) | 12 | | |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rhinalgia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Sneezing | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Upper-airway cough syndrome | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Wheezing | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Tonsillolith | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Bronchial hyperreactivity | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Increased upper airway secretion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pleuritic pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory disorder | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Throat clearing | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hiccups | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 8 / 906 (0.88%) | | |
| occurrences (all) | 8 | | |
| Anorexia nervosa | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Aggression | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Adjustment disorder with depressed mood | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Adjustment disorder | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Attention deficit hyperactivity disorder | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Anxiety disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Depression suicidal | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Disruptive mood dysregulation disorder | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Sleep disorder | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Panic attack | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Depression | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Binge eating | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Insomnia | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Stress | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Tic | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Suicidal ideation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Anger | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Acute stress disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Irritability | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Mixed anxiety and depressive disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Obsessive-compulsive disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| School refusal | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hallucination | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Investigations | | | |
| SARS-CoV-2 test positive | | | |
| subjects affected / exposed | 7 / 906 (0.77%) | | |
| occurrences (all) | 7 | | |
| Body temperature increased | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Cardiac murmur | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Computerised tomogram abdomen abnormal | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Heart rate irregular | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Liver function test increased | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Serum ferritin decreased | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Streptococcus test positive | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Thyroid hormones decreased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood pressure increased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Heart rate increased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Red blood cell count increased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injury, poisoning and procedural complications | | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Arthropod bite | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Arthropod sting | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Ankle fracture | | | |

| | | | |
|-----------------------------|------------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Clavicle fracture | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Ligament sprain | | | |
| subjects affected / exposed | 16 / 906 (1.77%) | | |
| occurrences (all) | 17 | | |
| Contusion | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Eye abrasion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fall | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Fibula fracture | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Foot fracture | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 6 | | |
| Hand fracture | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Head injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Human bite | | | |

| | | | |
|------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Humerus fracture | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Infusion related reaction | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Joint dislocation | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Joint injury | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Ligament rupture | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Concussion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Limb injury | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 5 | | |
| Skin abrasion | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 3 | | |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Muscle rupture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Muscle strain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal foreign body | | | |

| | | | |
|------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nail injury | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Post procedural complication | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Post-traumatic neck syndrome | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Procedural complication | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Procedural dizziness | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Procedural nausea | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Procedural vomiting | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Radius fracture | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Road traffic accident | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Scratch | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Lower limb fracture | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin laceration | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 5 | | |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tibia fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Torus fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Traumatic haematoma | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ulna fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Upper limb fracture | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 5 | | |
| Vaccination complication | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Wrist fracture | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Tendon injury | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Anaesthetic complication | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Animal bite | | | |

| | | | |
|-----------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Animal scratch | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tooth injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Bursa injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Compression fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear canal injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Foreign body in respiratory tract | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ligament injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Limb crushing injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Limb fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Musculoskeletal injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasal injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Post procedural haemorrhage | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Soft tissue injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sports injury | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Stress fracture | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sunburn | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Bone contusion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Traumatic haemorrhage | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Wound | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Congenital, familial and genetic disorders | | | |
| Multiple endocrine neoplasia Type 1 | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Rathke's cleft cyst | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Type V hyperlipidaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Familial mediterranean fever | | | |

| | | | |
|------------------------------|--------------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermoid cyst | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pectus excavatum | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Cardiac disorders | | | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Tachycardia paroxysmal | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nervous system disorders | | | |
| Dyskinesia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Dizziness | | | |
| subjects affected / exposed | 6 / 906 (0.66%) | | |
| occurrences (all) | 6 | | |
| Headache | | | |
| subjects affected / exposed | 525 / 906 (57.95%) | | |
| occurrences (all) | 874 | | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Taste disorder | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Syncope | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Speech disorder | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Somnolence | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Lethargy | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Migraine | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 5 | | |
| Myoclonus | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Neuromuscular blockade | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Presyncope | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Psychomotor hyperactivity | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Seizure | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Restless legs syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Carpal tunnel syndrome | | | |

| | | | |
|--------------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sleep deficit | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tension headache | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Lymphadenitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 7 / 906 (0.77%) | | |
| occurrences (all) | 7 | | |
| Coagulopathy | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Increased tendency to bruise | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear and labyrinth disorders | | | |
| Hypoacusis | | | |

| | | | |
|-------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Eustachian tube dysfunction | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Tympanic membrane perforation | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vertigo | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Cerumen impaction | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear pain | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Excessive cerumen production | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| External ear inflammation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Motion sickness | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tympanosclerosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye disorders | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| Astigmatism | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Eye pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Blepharitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Glaucoma | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Keratitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ocular hyperaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Swelling of eyelid | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Eye irritation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctivitis allergic | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Blindness transient | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye swelling | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |

| | | | |
|-----------------------------|------------------|--|--|
| Chalazion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctival haemorrhage | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye inflammation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eyelid exfoliation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myopia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 11 / 906 (1.21%) | | |
| occurrences (all) | 12 | | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Abdominal pain upper | | | |

| | | | |
|----------------------------------|------------------|--|--|
| subjects affected / exposed | 9 / 906 (0.99%) | | |
| occurrences (all) | 10 | | |
| Anal fissure | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Colitis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Constipation | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Dental caries | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 16 / 906 (1.77%) | | |
| occurrences (all) | 19 | | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Enteritis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Food poisoning | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Gastritis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Haematemesis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Haemorrhoids | | | |

| | | | |
|-----------------------------|--------------------|--|--|
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Hyperchlorhydria | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Irritable bowel syndrome | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Lip swelling | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nausea | | | |
| subjects affected / exposed | 204 / 906 (22.52%) | | |
| occurrences (all) | 262 | | |
| Oral pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Pancreatitis relapsing | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Peptic ulcer | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Toothache | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 6 | | |
| Vomiting | | | |
| subjects affected / exposed | 11 / 906 (1.21%) | | |
| occurrences (all) | 11 | | |
| Oral pruritus | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Aphthous ulcer | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Coeliac disease | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Embedded tooth | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eructation | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Flatulence | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Palatal disorder | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tongue discolouration | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Transient lingual papillitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gingival pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hepatobiliary disorders | | | |
| Hepatic steatosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Pityriasis | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Acne | | | |
| subjects affected / exposed | 7 / 906 (0.77%) | | |
| occurrences (all) | 7 | | |
| Cold urticaria | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Dermatitis allergic | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis atopic | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Dermatitis contact | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Eczema | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hand dermatitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Ingrowing nail | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Miliaria | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain of skin | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Pruritus | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Rash macular | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash pruritic | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin lesion | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Urticaria | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nail disorder | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Rash erythematous | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Seborrhoeic dermatitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin induration | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Urticaria chronic | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Haematuria | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nephritis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---|----------------------|--|--|
| Urinary retention subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Urinary tract inflammation subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Thyroid stimulating hormone deficiency subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Growth hormone deficiency subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Thyroid cyst subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Musculoskeletal and connective tissue disorders Joint swelling subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Muscular weakness subjects affected / exposed occurrences (all) | 3 / 906 (0.33%) 3 | | |
| Intervertebral disc protrusion subjects affected / exposed occurrences (all) | 1 / 906 (0.11%) 1 | | |
| Growing pains subjects affected / exposed occurrences (all) | 0 / 906 (0.00%) 0 | | |
| Foot deformity | | | |

| | | | |
|-----------------------------|--------------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Epiphysiolysis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Back pain | | | |
| subjects affected / exposed | 15 / 906 (1.66%) | | |
| occurrences (all) | 15 | | |
| Axillary mass | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Arthritis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Arthralgia | | | |
| subjects affected / exposed | 127 / 906 (14.02%) | | |
| occurrences (all) | 163 | | |
| Joint warmth | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Knee deformity | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Muscle swelling | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Muscle tightness | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Joint hyperextension | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Tenosynovitis | | | |

| | | | |
|----------------------------------|--------------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tendon pain | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Temporomandibular joint syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sever's disease | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 11 / 906 (1.21%) | | |
| occurrences (all) | 11 | | |
| Osteochondrosis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Neck pain | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Neck mass | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myositis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myalgia | | | |
| subjects affected / exposed | 209 / 906 (23.07%) | | |
| occurrences (all) | 276 | | |
| Musculoskeletal chest pain | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Rhabdomyolysis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Bone pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Coccydynia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Joint effusion | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Myokymia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Sacral pain | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Scoliosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Short stature | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Spinal flattening | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Synovial cyst | | | |

| | | | |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tendonitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Torticollis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infections and infestations | | | |
| Bacterial vaginosis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Acarodermatitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Acute sinusitis | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Adenovirus infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Asymptomatic COVID-19 | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Enterovirus infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Enterobiasis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Eye infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Eyelid infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|--------------------|--|--|
| Folliculitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 5 | | |
| Body tinea | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Bullous impetigo | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| COVID-19 | | | |
| subjects affected / exposed | 107 / 906 (11.81%) | | |
| occurrences (all) | 111 | | |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Cellulitis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Chlamydial infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Coronavirus infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Cystitis | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Ear infection | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |

| | | | |
|-----------------------------|-----------------|--|--|
| Endometritis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Erythema migrans | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 6 / 906 (0.66%) | | |
| occurrences (all) | 6 | | |
| Genital herpes | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Gingivitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Infected bite | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hordeolum | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Impetigo | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Helicobacter gastritis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |

| | | | |
|-----------------------------------|------------------|--|--|
| Localised infection | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Lyme disease | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Mycoplasma genitalium infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 37 / 906 (4.08%) | | |
| occurrences (all) | 42 | | |
| Onychomycosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oral herpes | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 6 | | |
| Otitis externa | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Otitis media | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Otitis media acute | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 2 | | |
| Otosalpingitis | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Paronychia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---------------------------------------|------------------|--|--|
| Parotitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pelvic inflammatory disease | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Pharyngitis | | | |
| subjects affected / exposed | 19 / 906 (2.10%) | | |
| occurrences (all) | 24 | | |
| Influenza | | | |
| subjects affected / exposed | 11 / 906 (1.21%) | | |
| occurrences (all) | 12 | | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Pulpitis dental | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory tract infection bacterial | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 7 / 906 (0.77%) | | |
| occurrences (all) | 8 | | |
| Rhinitis | | | |
| subjects affected / exposed | 8 / 906 (0.88%) | | |
| occurrences (all) | 8 | | |
| Rhinovirus infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Sialoadenitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|------------------|--|--|
| Sinusitis | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Skin infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Soft tissue infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Streptococcal infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Suspected COVID-19 | | | |
| subjects affected / exposed | 6 / 906 (0.66%) | | |
| occurrences (all) | 6 | | |
| Tinea versicolour | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tonsillitis | | | |
| subjects affected / exposed | 15 / 906 (1.66%) | | |
| occurrences (all) | 17 | | |
| Tonsillitis streptococcal | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Tooth abscess | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Tooth infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Yersinia infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tracheitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|------------------|--|--|
| Trichomoniasis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 42 / 906 (4.64%) | | |
| occurrences (all) | 46 | | |
| Upper respiratory tract infection bacterial | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 9 / 906 (0.99%) | | |
| occurrences (all) | 10 | | |
| Vaginal infection | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Varicella | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Viral infection | | | |
| subjects affected / exposed | 5 / 906 (0.55%) | | |
| occurrences (all) | 6 | | |
| Viral pharyngitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 906 (0.44%) | | |
| occurrences (all) | 4 | | |
| Vulvovaginal candidiasis | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Vulvovaginal mycotic infection | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Wound infection | | | |

| | | | |
|----------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Conjunctivitis viral | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Ear lobe infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fungal foot infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Fungal skin infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrointestinal viral infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hand-foot-and-mouth disease | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Helminthic infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Herpes simplex | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pericoronitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Parasitic gastroenteritis | | | |

| | | | |
|---------------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Post-acute COVID-19 syndrome | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory syncytial virus infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin bacterial infection | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site cellulitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vaccination site pustule | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vulvovaginitis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Laryngotracheitis obstructive | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Molluscum contagiosum | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pharyngotonsillitis | | | |

| | | | |
|------------------------------------|-----------------|--|--|
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Insulin resistance | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Iron deficiency | | | |
| subjects affected / exposed | 3 / 906 (0.33%) | | |
| occurrences (all) | 3 | | |
| Lactose intolerance | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Obesity | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Type 2 diabetes mellitus | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vitamin B complex deficiency | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vitamin B12 deficiency | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Abnormal loss of weight | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Glucose tolerance impaired | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gluten sensitivity | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|-----------------------------|-----------------|--|--|
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hyperlipidaemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Zinc deficiency | | | |
| subjects affected / exposed | 1 / 906 (0.11%) | | |
| occurrences (all) | 1 | | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 2 / 906 (0.22%) | | |
| occurrences (all) | 2 | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Haemochromatosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypovitaminosis | | | |
| subjects affected / exposed | 0 / 906 (0.00%) | | |
| occurrences (all) | 0 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--|
| 23 May 2019 | As per the recommendation from CBER, the scope of the study has been extended to include the 3-dose (0,2,6-M) schedule and an additional 2-dose schedule (0,6-M) along with the 2-dose (0,2-M) schedule planned originally. The study will assess the immunogenicity of the 2-dose and 3-doses vaccination with rMenB+OMV NZ vaccine along with effectiveness and safety. |
| 18 March 2020 | The scope of this post-marketing commitment study has been extended to demonstrate the effectiveness, immunogenicity and safety of GSK's investigational combined meningococcal ABCWY vaccine (from a phase III MenABCWY study) along with the rMenB+OMV NZ vaccine. |
| 23 September 2020 | This protocol is amended primarily as a consequence of feedback from regulatory authorities of participating countries following their review of Protocol Amendment 2. Additional changes have been made to improve the clarity of the text. |
| 09 May 2021 | The protocol is being amended to document the increase in blood volumes drawn at certain visits (Visit 2 and Visit 6). The allowed windows for study visits during special circumstances have also been widened to maintain subject visit compliance during the COVID-19 pandemic. Additionally, considering that some of the study interventions are combination products constituted of a device and biologic product (pre-filled syringes), the amended protocol provides instructions for collection of safety information related to the use of medical devices. The reporting period for pregnancies has also been updated in line with the current guidelines |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported